JP2022031784A - Bcma-targeted chimeric antigen receptor, and preparation method and use thereof - Google Patents
Bcma-targeted chimeric antigen receptor, and preparation method and use thereof Download PDFInfo
- Publication number
- JP2022031784A JP2022031784A JP2021190474A JP2021190474A JP2022031784A JP 2022031784 A JP2022031784 A JP 2022031784A JP 2021190474 A JP2021190474 A JP 2021190474A JP 2021190474 A JP2021190474 A JP 2021190474A JP 2022031784 A JP2022031784 A JP 2022031784A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- bcma
- chimeric antigen
- antigen receptor
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 136
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims abstract description 58
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims abstract description 56
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims abstract description 56
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 31
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 26
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 23
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 23
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 20
- 208000003950 B-cell lymphoma Diseases 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 239000013598 vector Substances 0.000 claims description 47
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 44
- 239000000427 antigen Substances 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 29
- 230000027455 binding Effects 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 17
- 230000008685 targeting Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 10
- 208000032839 leukemia Diseases 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000031146 intracellular signal transduction Effects 0.000 claims description 3
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 11
- 230000003834 intracellular effect Effects 0.000 abstract description 10
- 239000013604 expression vector Substances 0.000 abstract description 9
- 208000031223 plasma cell leukemia Diseases 0.000 abstract description 2
- 230000014509 gene expression Effects 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 30
- 210000004881 tumor cell Anatomy 0.000 description 27
- 238000011282 treatment Methods 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- 201000000050 myeloid neoplasm Diseases 0.000 description 11
- 210000004180 plasmocyte Anatomy 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 8
- 108700008625 Reporter Genes Proteins 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 7
- 241000713666 Lentivirus Species 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 102100035932 Cocaine- and amphetamine-regulated transcript protein Human genes 0.000 description 6
- 101000715592 Homo sapiens Cocaine- and amphetamine-regulated transcript protein Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 5
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 239000012228 culture supernatant Substances 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241001430294 unidentified retrovirus Species 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 239000007975 buffered saline Substances 0.000 description 4
- 101150058049 car gene Proteins 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 3
- 102000046935 human TNFRSF17 Human genes 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 2
- -1 CD137 Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 2
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000004986 primary T-cell Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- BKUKXOMYGPYFJJ-UHFFFAOYSA-N 2-ethylsulfanyl-1h-benzimidazole;hydrobromide Chemical compound Br.C1=CC=C2NC(SCC)=NC2=C1 BKUKXOMYGPYFJJ-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101150090209 HCST gene Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000003423 Mucocele Diseases 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 101150010855 cma gene Proteins 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000000787 conjunctival cancer Diseases 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 108010056030 retronectin Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Description
本発明は、生物医薬の分野に関し、より具体的に、BCMAを標的とするキメラ抗原受
容体およびその製造方法と使用に関する。
The present invention relates to the field of biopharmaceuticals, and more specifically to BCMA-targeted chimeric antigen receptors and methods and uses thereof.
BCMAはB細胞成熟抗原で、CD269またはTNFRSF17とも呼ばれ、腫瘍壊
死因子受容体スーパーファミリーのメンバーで、そのリガンドはB細胞活性化因子(BA
FF)および増殖誘導リガンド(APRIL)である。
BCMAとBAFFおよびAPRILの結合はNF-kBを活性化させ、抗アポトーシ
スBcl-2のメンバー、たとえばBcl-xLまたはBcl-2およびMcl-1の上
方調節を誘導する。BCMAとそのリガンドの相互作用は様々な面から体液免疫、B細胞
の生長、分化を調節することによって人体内環境の安定した平衡を維持する。
BCMA is a B cell maturation antigen, also called CD269 or TNFRSF17, a member of the tumor necrosis factor receptor superfamily, whose ligand is B cell activating factor (BA).
FF) and growth-inducing ligand (APRIL).
Binding of BCMA to BAFF and APRIL activates NF-kB and induces upregulation of anti-apoptotic Bcl-2 members such as Bcl-xL or Bcl-2 and Mcl-1. The interaction between BCMA and its ligands maintains a stable equilibrium of the human environment by regulating humoral immunity, B cell growth, and differentiation from various aspects.
BCMAの発現はB細胞系に限られ、形質芽球では、形質細胞および一部の成熟B細胞
で発現され、末梢B細胞の分化時に増加するが、一方、大半のB細胞、たとえばナイーブ
B細胞、メモリーB細胞や胚中心B細胞およびほかの器官では発現されない。BCMAの
発現は骨髄における長寿で、定着した形質細胞に重要であることが報告された。そのため
、BCMA欠陥マウスでは、骨髄における形質細胞は減少するが、脾臓における形質細胞
レベルは影響されない。成熟B細胞はBCMAノックアウトマウスにおいて正常に形質細
胞に分化する。BCMAノックアウトマウスは見かけはすべて正常で、健康そうで、しか
もB細胞の数が正常であるが、形質細胞は長期間生存することができない。
BCMA expression is confined to B cell lines, and in plasmablasts it is expressed in plasma cells and some mature B cells and increases during peripheral B cell differentiation, while most B cells, such as naive B cells, , Not expressed in memory B cells, germinal center B cells and other organs. BCMA expression has been reported to be important for established plasma cells for longevity in the bone marrow. Therefore, in BCMA-deficient mice, plasma cells in the bone marrow are reduced, but plasma cell levels in the spleen are not affected. Mature B cells normally differentiate into plasma cells in BCMA knockout mice. BCMA knockout mice are all normal in appearance, appear healthy, and have a normal number of B cells, but plasma cells cannot survive for long periods of time.
BCMAは悪性形質細胞でも高度発現され、たとえば多発性骨髄腫や形質細胞性白血病
、ホジキンリンパ腫の患者のHRS細胞でもBCMAが検出された。米国では、血液系の
悪性腫瘍は悪性腫瘍全体の約10%を占め、骨髄腫は悪性血液腫瘍全体の15%を占める
。文献では、BCMAの発現は多発性骨髄腫の疾患進展に関連することが報告された。B
CMA遺伝子は骨髄腫の検体では高度発現されるが、慢性リンパ性白血病、急性リンパ性
白血病、急性Tリンパ性白血病では発現レベルが低い。BCMAリガンドであるBAFF
およびAPRILを過剰発現するネズミモデルにおいて、B細胞リンパ腫が顕著に増殖す
る。BCMAと結合するリガンドはBCMAを発現する多発性骨髄腫の増殖と生存を調節
することができることが証明された。BCMAとBAFFおよびAPRILの結合は悪性
形質細胞を生存させることができるため、BCMAを発現する腫瘍細胞を消耗させ、BC
MAリガンドと受容体の間の相互作用を破壊することは、多発性骨髄腫またはほかのBC
MA陽性B細胞性悪性リンパ腫に対する治療効果を改善することができる。
BCMA is also highly expressed in malignant plasma cells, and BCMA was also detected in HRS cells of patients with multiple myeloma, plasma cell leukemia, and Hodgkin lymphoma, for example. In the United States, malignant tumors of the blood system make up about 10% of all malignant tumors, and myeloma accounts for 15% of all malignant hematological tumors. The literature reports that expression of BCMA is associated with disease progression in multiple myeloma. B
The CMA gene is highly expressed in myeloma specimens, but is less expressed in chronic lymphocytic leukemia, acute lymphocytic leukemia, and acute T lymphocytic leukemia. BAFF, a BCMA ligand
And in a murine model that overexpresses APRIL, B-cell lymphoma proliferates significantly. It has been demonstrated that a ligand that binds to BCMA can regulate the growth and survival of multiple myeloma expressing BCMA. Since the binding of BCMA to BAFF and APRIL can survive malignant plasma cells, it depletes tumor cells expressing BCMA and BC.
Disrupting the interaction between MA ligands and receptors can lead to multiple myeloma or other BCs.
The therapeutic effect on MA-positive B-cell malignant lymphoma can be improved.
多発性骨髄腫は、形質細胞腫またはケーラー病とも呼ばれ、難治性のB細胞系の悪性腫
瘍で、特徴は形質細胞の異常増殖で、形質細胞は白血球の種類の一つで、抗体を生成する
役割を担う。米国国立癌研究所によって2017年に発表されたデータでは、骨髄腫は腫
瘍症例全体の1.8%を占め、致死率が2.1%であることが示されている。2010年
-2014年の統計結果では、毎年の発症率が約10万分の6.6で、死亡率が約50%
であることが示されている。多発性骨髄腫は、中高年疾患に属し、欧米では発症年齢の中
央値は68歳で、男性は女性よりも多く、我が国の統計では、発症年齢のピークは55-
65歳で、男女比は2.35:1で、我が国では、多発性骨髄腫の確実な流行病学の調査
資料がまだないが、一般的に、発症率が周辺の東南アジアと日本に近く、約10万分の1
であると推測されている。多発性骨髄腫の従来の治療手段は、化学治療および造血幹細胞
移植を含むが、これらの方法は再発率が高い。ボルテゾミブ(PS-341)は初めての
プロテアソーム阻害剤で、2003年にFDAによって単独または既存薬物との併用で再
発性・難治性の多発性骨髄腫の治療への使用が許可され、結果は喜ばしいものであった。
当該薬物は2005年に中国でも市販され、現在、サリドマイド、デキサメタゾンなどと
ともに多発性骨髄腫の治療によく使用される選択の一つになっている。多発性骨髄腫の治
療方法は、通常、併用のものであるが、同時に複数の薬物を使用すると、費用が高価で、
副作用が累積するという、よくない結果もある。臨床では、多発性骨髄腫を治療する新規
な方法の開発がまだ切望されている。
Multiple myeloma, also called plasmacytoma or Koehler's disease, is a refractory B-cell malignancies characterized by overgrowth of plasma cells, which are a type of white blood cell that produce antibodies. Take on the role of Data published in 2017 by the National Cancer Institute show that myeloma accounts for 1.8% of all tumor cases and has a case fatality rate of 2.1%. According to the 2010-2014 statistics, the annual incidence rate is about 6.6 / 100,000 and the mortality rate is about 50%.
It is shown to be. Multiple myeloma belongs to middle-aged and elderly diseases. In Europe and the United States, the median age of onset is 68 years, and males are more common than females. According to Japanese statistics, the peak age of onset is 55-
At the age of 65, the male-female ratio is 2.35: 1, and although there is no reliable epidemiological survey material for multiple myeloma in Japan, the incidence is generally close to that of neighboring Southeast Asia and Japan. About 1 / 100,000
It is speculated that. Traditional treatments for multiple myeloma include chemotherapy and hematopoietic stem cell transplantation, but these methods have a high recurrence rate. Bortezomib (PS-341) is the first proteasome inhibitor and was approved by the FDA in 2003 for the treatment of relapsed and refractory multiple myeloma alone or in combination with existing drugs, and the results are pleasing. Met.
The drug was marketed in China in 2005 and is now one of the most commonly used choices for the treatment of multiple myeloma along with thalidomide, dexamethasone and the like. Treatment of multiple myeloma is usually a combination, but the use of multiple drugs at the same time is expensive and expensive.
There are also bad consequences of cumulative side effects. In clinical practice, the development of new methods for treating multiple myeloma is still eagerly awaited.
最近、免疫療法、特に養子T細胞療法は、血液系の悪性腫瘍を治療する臨床試験におい
て強い治療効果および明るい将来性が示されている。T細胞はキメラ抗原受容体(CAR
)を発現するように遺伝子修飾されてもよく、抗原認識部分およびT細胞活性化領域を含
む。CARはモノクローナル抗体の抗原結合の性質を利用してT細胞の特異性と反応性を
リダイレクトしてMHCに拘束されずにターゲッティングすることができる。このような
非MHC拘束性抗原認識によって、CARを発現するT細胞は抗原を加工せずに抗原を認
識するため、腫瘍の逃避の主な機序の一つが避けられる。そのほか、CARは内因性TC
Rのα鎖、β鎖と二量体になることがない。
Recently, immunotherapy, especially adoptive T cell therapy, has shown strong therapeutic effects and bright future in clinical trials for treating malignant tumors of the blood system. T cells are chimeric antigen receptors (CAR)
) May be genetically modified to include an antigen recognition moiety and a T cell activation region. CAR can utilize the antigen-binding properties of monoclonal antibodies to redirect the specificity and reactivity of T cells for targeting without being bound by MHC. By such non-MHC-restricted antigen recognition, CAR-expressing T cells recognize the antigen without processing the antigen, thus avoiding one of the main mechanisms of tumor escape. In addition, CAR is an endogenous TC
It does not become a dimer with the α chain and β chain of R.
現在、海外では既に2つのCD19を標的とするキメラ抗原受容体T細胞療法(CAR
-T)の製品が市販され、児童と若年の患者の急性リンパ性白血病の治療および成人の再
発性または難治性の大細胞型B細胞性リンパ腫の第二選択以上の治療に使用される。しか
しながら、CD19は多発性骨髄腫の悪性形質細胞において発現されることが少ない。本
分野では、多発性骨髄腫を治療する、BCMAを標的とするCAR-T製品の開発が切望
されている。
Currently, overseas, chimeric antigen receptor T cell therapy (CAR) already targets two CD19s.
-T) products are commercially available and are used in the treatment of acute lymphocytic leukemia in children and young patients and in the second and higher choices for relapsed or refractory large B-cell lymphoma in adults. However, CD19 is rarely expressed in malignant plasma cells of multiple myeloma. In this field, the development of CAR-T products targeting BCMA for treating multiple myeloma is eagerly desired.
発明の概要
本発明の目的は、BCMAを標的とするキメラ抗原受容体およびその製造方法と使用を
提供することにある。
具体的に、本発明の目的は、BCMA抗原を標的とするキメラ抗原受容体の配列、およ
びその修飾T細胞(CART-BCMA)の製造方法と活性同定を提供することにある。
Outline of the Invention An object of the present invention is to provide a chimeric antigen receptor targeting BCMA and a method for producing the same and its use.
Specifically, an object of the present invention is to provide a sequence of a chimeric antigen receptor targeting a BCMA antigen, and a method for producing and identifying the activity of modified T cells (CART-BCMA) thereof.
本発明は、BCMA陽性のB細胞性リンパ腫を治療するためのキメラ抗原受容体の構造
を提供する。
本発明の第一の側面では、キメラ抗原受容体(CAR)(配列)であって、前記キメラ
抗原受容体の抗原結合ドメインはBCMAを標的とする細胞外領域の抗体一本鎖可変領域
の配列であるものを提供する。
もう一つの好適な例において、前記の抗原結合ドメインはBCMA配列の24~41番
目のアミノ酸残基を標的とする抗体一本鎖可変領域の配列である。
もう一つの好適な例において、前記のBCMA配列のNCBI登録番号はAY6849
75.1である。
The present invention provides the structure of a chimeric antigen receptor for treating BCMA-positive B-cell lymphoma.
In the first aspect of the present invention, it is a chimeric antigen receptor (CAR) (sequence), and the antigen binding domain of the chimeric antigen receptor is a sequence of an antibody single-stranded variable region in an extracellular region targeting BCMA. Provide what is.
In another preferred example, the antigen-binding domain is a sequence of antibody single-stranded variable regions targeting amino acid residues 24-41 of the BCMA sequence.
In another preferred example, the NCBI registration number for the BCMA sequence is AY6849.
75.1.
もう一つの好適な例において、前記の抗原結合ドメインの構造は、下記式Iで表され
る。
VL-VH (I)
(ただし、VHは抗体の重鎖可変領域で、VLは抗体の軽鎖可変領域で、「-」は連結
ペプチドまたはペプチド結合である。
かつ、VLのアミノ酸配列は配列番号1で示され、VHのアミノ酸配列は配列番号2で
示され、
あるいは、VLのアミノ酸配列は配列番号3で示され、VHのアミノ酸配列は配列番号
4で示され、
あるいは、VLのアミノ酸配列は配列番号5で示され、VHのアミノ酸配列は配列番号
6で示される。)
In another preferred example, the structure of the antigen binding domain is represented by Formula I below.
VL - VH (I)
(However, VE is the heavy chain variable region of the antibody, VL is the light chain variable region of the antibody, and "-" is a linked peptide or peptide bond.
Moreover, the amino acid sequence of VL is shown by SEQ ID NO: 1, and the amino acid sequence of VL is shown by SEQ ID NO: 2.
Alternatively, the amino acid sequence of VL is shown by SEQ ID NO: 3, and the amino acid sequence of VL is shown by SEQ ID NO: 4.
Alternatively, the amino acid sequence of VL is shown by SEQ ID NO: 5, and the amino acid sequence of VL is shown by SEQ ID NO: 6. )
もう一つの好適な例において、前記の連結ペプチドのアミノ酸配列は配列番号10ま
たは配列番号11で示される。
もう一つの好適な例において、前記の抗体一本鎖可変領域はヒト化の抗体一本鎖可変領
域、ネズミ由来の抗体一本鎖可変領域、ヒトとネズミのキメラの抗体一本鎖可変領域であ
る。
もう一つの好適な例において、前記キメラ抗原受容体の構造は、下記式IIで表される
。
S-VL-VH-H-TM-C-CD3ζ (II)
(ただし、
Sは任意のシグナルペプチド(すなわちsignal peptide)である。
Hはヒンジ領域である。
TMは膜貫通ドメインである。
Cは共刺激シグナル分子である。
CD3ζはCD3ζ由来の細胞内シグナル伝達配列である。
VHとVLはそれぞれ上記の通りである。)
In another preferred example, the amino acid sequence of the linked peptide is set forth by SEQ ID NO: 10 or SEQ ID NO: 11.
In another preferred example, the antibody single-stranded variable region described above is a humanized antibody single-stranded variable region, a murine-derived antibody single-stranded variable region, or a human-rat chimeric antibody single-stranded variable region. be.
In another preferred example, the structure of the chimeric antigen receptor is represented by Formula II below.
S-V L -V H -H-TM-C-CD3ζ (II)
(However,
S is any signal peptide (ie, signal peptide).
H is a hinge region.
TM is a transmembrane domain.
C is a co-stimulation signal molecule.
CD3ζ is an intracellular signal transduction sequence derived from CD3ζ.
V H and V L are as described above, respectively. )
もう一つの好適な例において、前記のSは、CD8、CD28、GM-CSF、CD4
、CD137、またはこれらの組み合わせからなる群から選ばれるタンパク質のシグナル
ペプチドである。
もう一つの好適な例において、前記のSは、CD8由来のシグナルペプチドである。
もう一つの好適な例において、Sのアミノ酸配列は、配列番号9で示される。
In another preferred example, the S is CD8, CD28, GM-CSF, CD4.
, CD137, or a signal peptide of a protein selected from the group consisting of combinations thereof.
In another preferred example, the S is a CD8-derived signal peptide.
In another preferred example, the amino acid sequence of S is set forth in SEQ ID NO: 9.
もう一つの好適な例において、前記のHは、CD8、CD28、CD137、またはこ
れらの組み合わせからなる群から選ばれるタンパク質のヒンジ領域である。
もう一つの好適な例において、前記のHは、CD8由来のヒンジ領域である。
もう一つの好適な例において、Hのアミノ酸配列は、配列番号12で示される。
In another preferred example, said H is the hinge region of a protein selected from the group consisting of CD8, CD28, CD137, or a combination thereof.
In another preferred example, the H is a hinge region derived from CD8.
In another preferred example, the amino acid sequence of H is set forth in SEQ ID NO: 12.
もう一つの好適な例において、前記のTMは、CD28、CD3ε、CD45、CD4
、CD5、CD8、CD9、CD16、CD22、CD33、CD37、CD64、CD
80、CD86、CD134、CD137、CD154、またはこれらの組み合わせから
なる群から選ばれるタンパク質の膜貫通ドメインである。
もう一つの好適な例において、前記のTMは、CD8由来の膜貫通ドメインである。
もう一つの好適な例において、TMの配列は、配列番号13で示される。
In another preferred example, the TM is CD28, CD3ε, CD45, CD4.
, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD
A transmembrane domain of a protein selected from the group consisting of 80, CD86, CD134, CD137, CD154, or a combination thereof.
In another preferred example, the TM is a CD8-derived transmembrane domain.
In another preferred example, the sequence of TM is set forth in SEQ ID NO: 13.
もう一つの好適な例において、前記のCは、OX40、CD2、CD7、CD27、C
D28、CD30、CD40、CD70、CD134、4-1BB(CD137)、PD
1、Dap10、CDS、ICAM-1、LFA-1(CD11a/CD18)、ICO
S(CD278)、NKG2D、GITR、TLR2、またはこれらの組み合わせからな
る群から選ばれるタンパク質の共刺激シグナル分子である。
もう一つの好適な例において、前記のCは、4-1BB由来の共刺激シグナル分子であ
る。
もう一つの好適な例において、Cのアミノ酸配列は、配列番号14で示される。
もう一つの好適な例において、CD3ζのアミノ酸配列は、配列番号15で示される。
In another preferred example, the C is OX40, CD2, CD7, CD27, C.
D28, CD30, CD40, CD70, CD134, 4-1BB (CD137), PD
1, Dap10, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICO
It is a protein co-stimulation signal molecule selected from the group consisting of S (CD278), NKG2D, GITR, TLR2, or a combination thereof.
In another preferred example, C is a co-stimulation signal molecule derived from 4-1BB.
In another preferred example, the amino acid sequence of C is set forth in SEQ ID NO: 14.
In another preferred example, the amino acid sequence of CD3ζ is set forth by SEQ ID NO: 15.
本発明の第二の側面では、本発明の第一の側面に記載のキメラ抗原受容体(CAR)を
コードする核酸分子を提供する。
もう一つの好適な例において、前記核酸分子は単離されたものである。
本発明の第三の側面では、本発明の第二の側面に記載の核酸分子を含むベクターを提供
する。
もう一つの好適な例において、前記のベクターは、DNA、RNA、プラスミド、レン
チウイルスベクター、アデノウイルスベクター、レトロウイルスベクター、トランスポゾ
ン、またはこれらの組み合わせからなる群から選ばれる。
もう一つの好適な例において、前記ベクターはレンチウイルスベクターである。
A second aspect of the invention provides a nucleic acid molecule encoding the chimeric antigen receptor (CAR) described in the first aspect of the invention.
In another preferred example, the nucleic acid molecule is isolated.
A third aspect of the invention provides a vector comprising the nucleic acid molecule described in the second aspect of the invention.
In another preferred example, the vector is selected from the group consisting of DNA, RNA, plasmids, lentiviral vectors, adenoviral vectors, retroviral vectors, transposons, or combinations thereof.
In another preferred example, the vector is a lentiviral vector.
本発明の第四の側面では、本発明の第三の側面に記載のベクターを含有するか、あるい
は染色体に外来の本発明の第二の側面に記載の核酸分子が組み込まれたか、あるいは本発
明の第一の側面に記載のCARを発現する宿主細胞を提供する。
もう一つの好適な例において、前記細胞は単離された細胞で、および/または前記細胞
は遺伝子改変された細胞である。
もう一つの好適な例において、前記細胞は哺乳動物の細胞である。
もう一つの好適な例において、前記細胞はT細胞である。
In the fourth aspect of the invention, the vector according to the third aspect of the present invention is contained, or the chromosomal nucleic acid molecule described in the second aspect of the present invention is incorporated into the chromosome, or the present invention. Provided are host cells expressing the CAR described in the first aspect of the invention.
In another preferred example, the cell is an isolated cell and / or the cell is a genetically modified cell.
In another preferred example, the cell is a mammalian cell.
In another preferred example, the cell is a T cell.
本発明の第五の側面では、CAR-T細胞を製造する方法であって、前記のCAR-T
細胞は本発明の第一の側面に記載のCARを発現し、
本発明の第二の側面に記載の核酸分子または本発明の第三の側面に記載のベクターをT
細胞内に形質導入することによって、前記CAR-T細胞を得る工程、
を含む方法を提供する。
A fifth aspect of the present invention is a method for producing CAR-T cells, which is the above-mentioned CAR-T.
The cells express the CAR described in the first aspect of the invention and
The nucleic acid molecule described in the second aspect of the present invention or the vector described in the third aspect of the present invention is T.
The step of obtaining the CAR-T cells by transducing them into cells,
Provide methods including.
本発明の第六の側面では、本発明の第一の側面に記載のキメラ抗原受容体、本発明の第
二の側面に記載の核酸分子、本発明の第三の側面に記載のベクター、または本発明の第四
の側面に記載の細胞と、薬学的に許容される担体、希釈剤または賦形剤とを含有する薬物
組成物を提供する。
もう一つの好適な例において、前記製剤は液体製剤である。
もう一つの好適な例において、前記製剤の剤形は注射剤である。
もう一つの好適な例において、前記製剤で、前記CAR-T細胞の濃度が1×103~
1×108細胞/mL、好ましくは1×104~1×107細胞/mLである。
In the sixth aspect of the invention, the chimeric antigen receptor described in the first aspect of the invention, the nucleic acid molecule described in the second aspect of the invention, the vector described in the third aspect of the invention, or. Provided is a drug composition containing the cells according to the fourth aspect of the present invention and a pharmaceutically acceptable carrier, diluent or excipient.
In another preferred example, the formulation is a liquid formulation.
In another preferred example, the dosage form of the formulation is an injection.
In another suitable example, in the above-mentioned preparation, the concentration of the CAR-T cells is 1 × 10 3 ~.
It is 1 × 10 8 cells / mL, preferably 1 × 10 4 to 1 × 10 7 cells / mL.
本発明の第七の側面では、本発明の第一の側面に記載のキメラ抗原受容体、本発明の第
二の側面に記載の核酸分子、本発明の第三の側面に記載のベクター、または本発明の第四
の側面に記載の細胞の使用であって、癌または腫瘍を予防および/または治療する薬物ま
たは製剤の製造における使用を提供する。
もう一つの好適な例において、前記腫瘍は、血液腫瘍、固形腫瘍、またはこれらの組み
合わせからなる群から選ばれる。
もう一つの好適な例において、前記血液腫瘍は、急性骨髄球性白血病(AML)、多発
性骨髄腫(MM)、慢性リンパ性白血病(CLL)、急性リンパ性白血病(ALL)、び
まん性大細胞型B細胞性リンパ腫(DLBCL)、またはこれらの組み合わせからなる群
から選ばれる。
In the seventh aspect of the invention, the chimeric antigen receptor described in the first aspect of the invention, the nucleic acid molecule described in the second aspect of the invention, the vector described in the third aspect of the invention, or. The use of cells according to a fourth aspect of the invention, provided for use in the manufacture of a drug or formulation that prevents and / or treats cancer or tumor.
In another preferred example, the tumor is selected from the group consisting of hematological tumors, solid tumors, or combinations thereof.
In another preferred example, the hematological malignancies are acute myelocytic leukemia (AML), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), diffuse large cells. It is selected from the group consisting of type B cell lymphoma (DLBCL) or a combination thereof.
もう一つの好適な例において、前記の固形腫瘍は、胃癌、胃癌腹膜転移、肝臓癌、白血
病、腎臓腫瘍、肺癌、小腸癌、骨癌、前立腺癌、結直腸癌、乳癌、大腸癌、子宮頸癌、卵
巣癌、リンパ癌、鼻咽頭癌、副腎腫瘍、膀胱腫瘍、非小細胞肺癌(NSCLC)、脳膠細
胞腫、子宮内膜癌、またはからなる群から選ばれる。
もう一つの好適な例において、前記の腫瘍は、BCMA陽性腫瘍、好ましくはBCMA
陽性のB細胞性リンパ腫、多発性骨髄腫、または形質細胞性白血病である。
In another preferred example, the solid tumors are gastric cancer, gastric cancer peritoneal metastasis, liver cancer, leukemia, kidney tumor, lung cancer, small bowel cancer, bone cancer, prostate cancer, conjunctival cancer, breast cancer, colon cancer, cervix. It is selected from the group consisting of cancer, ovarian cancer, lymphoma, nasopharyngeal cancer, adrenal tumor, bladder tumor, non-small cell lung cancer (NSCLC), gliocytoma, endometrial cancer, or.
In another preferred example, the tumor is a BCMA positive tumor, preferably BCMA.
Positive B-cell lymphoma, multiple myeloma, or plasmacytotic leukemia.
本発明の第八の側面では、本発明の第四の側面に記載の細胞を製造するためのキットで
あって、容器と、容器内にある本発明の第二の側面に記載の核酸分子、または本発明の第
三の側面に記載のベクターを含むキットを提供する。
本発明の第九の側面では、本発明の第四の側面に記載の細胞、または本発明の第六の側
面に記載の製剤の使用であって、癌または腫瘍の予防および/または治療における使用を
提供する。
In the eighth aspect of the present invention, a kit for producing the cells according to the fourth aspect of the present invention, the container and the nucleic acid molecule according to the second aspect of the present invention in the container. Alternatively, a kit containing the vector according to the third aspect of the present invention is provided.
A ninth aspect of the invention is the use of the cell according to the fourth aspect of the invention, or the formulation according to the sixth aspect of the invention, for use in the prevention and / or treatment of cancer or tumor. I will provide a.
本発明の第十の側面では、疾患を治療する方法であって、治療が必要な対象に適量の本
発明の第四の側面に記載の細胞、および/または本発明の第六の側面に記載の製剤を施用
する工程を含む方法を提供する。
もう一つの好適な例において、前記疾患は癌または腫瘍である。
もちろん、本発明の範囲内において、本発明の上記の各技術特徴および下記(たとえば
実施例)の具体的に記述された各技術特徴は互いに組み合わせ、新しい、または好適な技
術方案を構成できることが理解される。紙数に限りがあるため、ここで逐一説明しない。
A tenth aspect of the invention is a method of treating a disease, wherein an appropriate amount of the cells according to the fourth aspect of the present invention and / or the sixth aspect of the present invention is described for a subject in need of treatment. Provided is a method including a step of applying the preparation of the above.
In another preferred example, the disease is cancer or tumor.
Of course, within the scope of the present invention, it is understood that the above-mentioned technical features of the present invention and the specifically described technical features below (for example, Examples) can be combined with each other to form a new or suitable technical plan. Will be done. Since the number of papers is limited, I will not explain it here one by one.
具体的な実施形態
本発明者らは、幅広く深く研究し、大量のスクリーニングを行ったところ、初めてBC
MA抗原を標的とするキメラ抗原受容体を得た。具体的に、本発明では、BCMA-1、
BCMA-20、BCMA-CA8、BCMA-MO6の4つのモノクローナル抗体配列
に基づいて構築されたBCMAを標的とするキメラ抗原受容体の構造を獲得し、そしてこ
れらのキメラ抗原受容体の初代T細胞における発現レベル、体外活性化能力および腫瘍細
胞殺傷力などの面における分析と同定を完成させた。研究では、本発明のキメラ抗原受容
体は、BCMA陽性細胞を標的とし、BCMA陽性のB細胞性リンパ腫、多発性骨髄腫、
形質細胞性白血病またはほかの疾患の治療に使用することができることが明らかになった
。
Specific Embodiment The present inventors have conducted extensive and in-depth research and conducted a large amount of screening, and for the first time, BC
A chimeric antigen receptor targeting the MA antigen was obtained. Specifically, in the present invention, BCMA-1,
Acquired BCMA-targeting chimeric antigen receptor structures constructed on the basis of four monoclonal antibody sequences, BCMA-20, BCMA-CA8, BCMA-MO6, and these chimeric antigen receptors in primary T cells. Completed analysis and identification in terms of expression levels, in vitro activation capacity and tumor cell killing power. In the study, the chimeric antigen receptors of the invention targeted BCMA-positive cells, BCMA-positive B-cell lymphoma, multiple myeloma,
It has been shown that it can be used to treat plasmacytoid leukemia or other diseases.
具体的に、本発明では、異なるCAR構造とウイルス感染後の細胞膜表面における発現
時間および発現強度の関連性を同定し、さらに異なるCAR構造のタンパク質発現の難易
度の違いを同定したが、この発見はCAR構造によって同様の感染条件においてCARタ
ンパク質の膜表面における発現レベルおよびCARTの体内活性の持続性が変わることを
示唆する。大量のスクリーニングによって、本発明の構造のCARを得たが、結果から、
本発明におけるCAR構造によってコードされるタンパク質がいずれも十分な発現と膜局
在化ができることが示された。
本発明において、BCMA抗原を標的とするCAR構造で修飾されたT細胞の製造プロ
セスを改良し、主に1%ヒト血清アルブミンを添加したGT-551無血清培地で体外で
リンパ球を培養した。
Specifically, in the present invention, the relationship between the different CAR structures and the expression time and the expression intensity on the cell membrane surface after virus infection was identified, and further, the difference in the difficulty of protein expression of different CAR structures was identified. Suggests that the CAR structure alters the expression level of CAR protein on the membrane surface and the persistence of CART activity in the body under similar infection conditions. A large amount of screening gave CAR of the structure of the present invention, but from the results,
It was shown that all the proteins encoded by the CAR structure in the present invention are capable of sufficient expression and membrane localization.
In the present invention, the process for producing T cells modified with a CAR structure targeting BCMA antigen was improved, and lymphocytes were cultured in vitro in GT-551 serum-free medium supplemented mainly with 1% human serum albumin.
用語
本開示が理解しやすくなるように、まず、一部の用語を定義する。本願に用いられるよ
うに、本明細書で別途に明確に規定しない限り、以下の用語はいずれも下記の意味を有す
る。出願全体において、ほかの定義が記述されている。
用語「約」とは当業者によって決定される特定の値または組成の許容される誤差範囲内
にある値または組成で、それによって部分的にどのように値または組成を計量または測定
するかというのが決まる。
用語「投与」とは当業者に既知の様々な方法および送達システムの任意の一つによって
本発明の製品を物理的に被験者に導入することで、静脈内、筋肉内、皮下、腹膜内、脊髄
またはほかの胃腸外の投与経路、たとえば注射または輸注によるものを含む。
Terms To make this disclosure easier to understand, we first define some terms. As used herein, all of the following terms have the following meanings, unless expressly specified herein. Other definitions are given throughout the application.
The term "about" is a value or composition within an acceptable error range of a particular value or composition determined by one of ordinary skill in the art, thereby partially measuring or measuring the value or composition. Is decided.
The term "administration" means intravenous, intramuscular, subcutaneous, intraperitoneal, spinal cord by physically introducing the product of the invention into a subject by any one of various methods and delivery systems known to those of skill in the art. Or other extragastrointestinal routes of administration, such as by injection or infusion.
用語「抗体」(Ab)はグロブリンを含むが、これに限定されず、特異的に抗原に結合
し、かつジスルフィド結合を介して互いに連結した少なくとも2本の重(H)鎖および2
本の軽(L)鎖あるいはその抗原結合部分を含む。各H鎖は、重鎖可変領域(本明細書で
VHと略する)および重鎖定常領域を含む。重鎖定常領域は、3つの定常ドメインCH1
、CH2およびCH3を含む。各軽鎖は、軽鎖可変領域(本明細書でVLと略する)およ
び軽鎖定常領域を含む。軽鎖定常領域は、1つの定常ドメインCLを含む。VHとVL領
域はさらに相補性決定領域(CDR)と呼ばれる超可変領域に細分してもよく、これらは
フレームワーク領域(FR)と呼ばれるより保存的な領域に散在している。各VHとVL
は3つのCDRと4つのFRを含み、アミノ末端からカルボキシ末端までFR1、CDR
1、FR2、CDR2、FR3、CDR3、FR4の順で並ぶ。重鎖と軽鎖の可変領域は
抗原と相互作用する結合ドメインを含有する。
The term "antibody" (Ab) includes, but is not limited to, at least two heavy (H) chains and 2 that specifically bind to the antigen and are linked to each other via a disulfide bond.
Includes a light (L) chain of a book or an antigen binding portion thereof. Each H chain contains a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is the three constant domains CH1.
, CH2 and CH3. Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region contains one constant domain CL. The VH and VL regions may be further subdivided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed in more conservative regions called framework regions (FRs). Each VH and VL
Contains 3 CDRs and 4 FRs, FR1 from the amino terminus to the carboxy terminus, CDR
1, FR2, CDR2, FR3, CDR3, FR4 are arranged in this order. The variable regions of the heavy and light chains contain binding domains that interact with the antigen.
キメラ抗原受容体(CAR)
本発明のキメラ抗原受容体(CAR)は、細胞外ドメイン、膜貫通ドメイン、および細
胞内ドメインを含む。細胞外ドメインは、標的特異的結合エレメント(抗原結合ドメイン
とも呼ばれる)を含む。細胞内ドメインは、共刺激シグナル伝達領域およびζ鎖部分を含
む。共刺激シグナル伝達領域は、共刺激分子の細胞内ドメインの一部を含む。共刺激分子
は、リンパ球の抗原に対する有効な応答に必要な細胞表面分子で、抗原受容体またはその
リガンドではない。
Chimeric antigen receptor (CAR)
The chimeric antigen receptor (CAR) of the present invention includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain comprises a target-specific binding element (also referred to as an antigen binding domain). The intracellular domain contains the co-stimulation signaling region and the ζ chain portion. The co-stimulation signaling region contains a portion of the intracellular domain of the co-stimulation molecule. A co-stimulator is a cell surface molecule required for an effective response of lymphocytes to an antigen, not an antigen receptor or its ligand.
CARの細胞外ドメインと膜貫通ドメインの間、またはCARの細胞内ドメインと膜貫
通ドメインの間に、リンカーを導入してもよい。本明細書で用いられるように、用語「リ
ンカー」とは、通常、膜貫通ドメインをポリペプチド鎖の細胞外ドメインまたは細胞内ド
メインに連結させる作用を果たす任意のオリゴペプチドまたはポリペプチドをいう。リン
カーは、0~300個のアミノ酸、好ましくは2~100個のアミノ酸、最も好ましくは
3~50個のアミノ酸を含んでもよい。
本発明の一つの好適な実施形態において、本発明によって提供されるCARの細胞外ド
メインはBCMAを標的とする抗原結合ドメインを含む。本発明のCARがT細胞におい
て発現される場合、抗原結合の特異性に基づいて抗原を認識することができる。それが関
連抗原に結合すると、腫瘍細胞に影響し、腫瘍細胞が成長せず、死亡するように、または
ほかの形で影響され、そして患者の腫瘍負荷が軽減または解消する。抗原結合ドメインは
、共刺激分子およびζ鎖から由来する一つまたは複数の細胞内ドメインと融合することが
好ましい。好ましくは、抗原結合ドメインは4-1BBシグナル伝達ドメイン、およびC
D3ζシグナルドメインと組み合わせた細胞内ドメインと融合している。
A linker may be introduced between the extracellular domain and transmembrane domain of CAR, or between the intracellular domain and transmembrane domain of CAR. As used herein, the term "linker" usually refers to any oligopeptide or polypeptide that acts to link the transmembrane domain to the extracellular or intracellular domain of the polypeptide chain. The linker may contain 0 to 300 amino acids, preferably 2 to 100 amino acids, most preferably 3 to 50 amino acids.
In one preferred embodiment of the invention, the extracellular domain of CAR provided by the invention comprises an antigen binding domain that targets BCMA. When the CAR of the present invention is expressed in T cells, the antigen can be recognized based on the specificity of antigen binding. When it binds to the associated antigen, it affects the tumor cells, causing them to not grow, die, or otherwise be affected, and reduce or eliminate the patient's tumor burden. The antigen binding domain is preferably fused with one or more intracellular domains derived from the co-stimulator molecule and the ζ chain. Preferably, the antigen binding domain is the 4-1BB signaling domain, and C.
It is fused with the intracellular domain combined with the D3ζ signal domain.
本明細書で用いられるように、「抗原結合ドメイン」、「一本鎖抗体断片」とはいずれ
も抗原結合活性を有するFab断片、Fab’断片、F(ab’)2断片、または単一の
Fv断片である。Fv抗体は抗体の重鎖可変領域、軽鎖可変領域を含有するが、定常領域
がなく、かつすべての抗原結合部位を有する最小の抗体断片である。一般的に、Fv抗体
はさらにVHとVLドメインの間のポリペプチドリンカーを含み、かつ抗原結合に必要な
構造を形成することができる。抗原結合ドメインは、通常、scFv(single-chain var
iable fragment、一本鎖可変断片)である。scFvの大きさは、通常、完全の抗体の1
/6である。一本鎖抗体は一本のヌクレオチド鎖によってコードされる一本のアミノ酸鎖
配列が好ましい。本発明の好適な形態として、前記scFvは特異的にBCMA細胞外領
域を認識する抗体、特に特異的にBCMA配列の24-41番目のアミノ酸残基を認識す
る抗体を含み、好ましくは一本鎖抗体である。
As used herein, an "antigen-binding domain" or "single-chain antibody fragment" is a Fab fragment, Fab'fragment, F (ab') 2 fragment, or a single fragment having antigen-binding activity. It is an Fv fragment. The Fv antibody is the smallest antibody fragment containing a heavy chain variable region and a light chain variable region of an antibody, but without a constant region and having all antigen binding sites. In general, Fv antibodies further include a polypeptide linker between the VH and VL domains and can form the structures required for antigen binding. The antigen-binding domain is usually scFv (single-chain var).
iable fragment, single-stranded variable fragment). The magnitude of scFv is usually one of the complete antibodies.
/ 6. The single-chain antibody preferably has a single amino acid chain sequence encoded by a single nucleotide chain. As a preferred embodiment of the invention, the scFv comprises an antibody that specifically recognizes the extracellular space of BCMA, particularly an antibody that specifically recognizes the 24-41th amino acid residue of the BCMA sequence, preferably single chain. It is an antibody.
ヒンジ領域と膜貫通領域(膜貫通ドメイン)について、CARはCARの細胞外ドメイ
ンに融合した膜貫通ドメインを含むように設計してもよい。一つの実施形態において、天
然のCARにおけるドメインの一つと関連する膜貫通ドメインが使用される。一部の例に
おいて、膜貫通ドメインを選択するか、アミノ酸置換で修飾することによって、このよう
なドメインが同様または相異の表面膜タンパク質の膜貫通ドメインに結合することを避け
ることで、受容体複合体のほかのメンバーとの相互作用を最小限にする。
本発明のCARにおける細胞内ドメインは、4-1BBのシグナル伝達ドメインおよび
CD3ζのシグナル伝達ドメインを含む。
For the hinge region and transmembrane domain (transmembrane domain), the CAR may be designed to include a transmembrane domain fused to the extracellular domain of CAR. In one embodiment, a transmembrane domain associated with one of the domains in natural CAR is used. In some examples, the receptor by selecting a transmembrane domain or modifying it with an amino acid substitution to prevent such a domain from binding to a transmembrane domain of a similar or different surface membrane protein. Minimize interaction with other members of the complex.
The intracellular domain in CAR of the present invention includes the signal transduction domain of 4-1BB and the signal transduction domain of CD3ζ.
好ましくは、本発明のCARの構造は、シグナルペプチド、抗原認識配列(抗原結合ド
メイン)、連結領域、膜貫通領域、共刺激因子シグナル領域およびCD3ζシグナル伝達
領域(ζ鎖部分)を含み、連結順は以下の通りである。
[CD8 S]-[VL-リンカー-VH]-[ヒンジ-CD8TM]-[4-1BB
]-[CD3ζ]
具体的に、本発明で使用される配列は以下の通りである。
(1)シグナルペプチドである、CD8由来のシグナルペプチド配列:
MALPVTALLLPLALLLHAARP (配列番号9)
(2)BCMA-1抗体由来の一本鎖の軽鎖可変領域(VL)配列:
DIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIHW
YQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTI
DPVEEDDVAVYYCLQSRTIPRTFGGGTKLEIK (配列番号7)
(3)BCMA-1抗体由来の一本鎖の重鎖可変領域(VH)配列:
QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKR
APGKGLKWMGWINTETREPAYAYDFRGRFAFSLETSASTA
YLQINNLKYEDTATYFCALDYSYAMDYWGQGTSVTVSS (
配列番号8)
ここで、BCMA-1は、既に発表されたCar-T配列に含まれる抗体配列で、本願
において対照として使用される。
Preferably, the structure of the CAR of the present invention comprises a signal peptide, an antigen recognition sequence (antigen binding domain), a linking region, a transmembrane domain, a co-stimulator signal region and a CD3ζ signal transduction region (ζ chain portion), in order of linkage. Is as follows.
[ CD8 S ]-[VL-Linker-VH]-[Hinge-CD8TM]-[4-1BB]
]-[CD3ζ]
Specifically, the sequences used in the present invention are as follows.
(1) CD8-derived signal peptide sequence, which is a signal peptide:
MALPVTALLLPLALLHAARP (SEQ ID NO: 9)
(2) Single-stranded light chain variable region (VL) sequence derived from BCMA-1 antibody:
DIVLTQSPPSLAMSLGKRATISCRASESVTILGSHLIHW
YQQKPGQPPTLLIQLASNVQTGVPARFSGSGSRTDFTLTI
DPVEEDDVAVYYCLQSRTIPRTFGGTKLEIK (SEQ ID NO: 7)
(3) Single-stranded heavy chain variable region (VH) sequence derived from BCMA-1 antibody:
QIQLVQSGPELKKPGETVKISCKASGYTFTDYSINWVKR
APGKGLKWMGWINTETREPAYAYDFRGRFAFSLETSASTA
YLQINNLKYEDTATYFCALDYSYAMDYWGQGTSVTVSS (
SEQ ID NO: 8)
Here, BCMA-1 is an antibody sequence contained in the previously announced Car-T sequence and is used as a control in the present application.
(4)BCMA-20抗体由来の一本鎖の軽鎖可変領域(VL)配列:
DIQMTQSPSSLSASVGDRVTITCRASQGISNYLNWYQQK
PGKAPKPLIYYTSNLQSGVPSRFSGSGSGTDYTLTISSLQ
PEDFATYYCMGQTISSYTFGQGTKLEIK (配列番号1)
(5)BCMA-20抗体由来の一本鎖の重鎖可変領域(VH)配列:
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMAWVRQ
APGKGLVWVSSITTGADHAIYADSVKGRFTISRDNAKNTL
YLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTV
SS (配列番号2)
(6)BCMA-CA8抗体由来の一本鎖の軽鎖可変領域(VL)配列:
DIQLTQTTSSLSASLGDRVTISCSASTTTSNYLNWYQQK
PDGTVELVIYYTSNLHGGGPSRFSGSGSGTDYSLTIGYLE
PEDVATYYCQQYRKLPWTFGGGSKLEIKR (配列番号3)
(7)BCMA-CA8抗体由来の一本鎖の重鎖可変領域(VH)配列:
EVQLQQSGAVLARPGASVKMSCKGSGYTFTNYWMHWVKQ
RPGQGLEWIGATYRGHSDTYYNQKFKGKAKLTAVTSTSTA
YMELSSLTNEDSAVYYCTRGAIYNGYDVLDNWGQGTLVTV
SS (配列番号4)
(4) Single-stranded light chain variable region (VL) sequence derived from BCMA-20 antibody:
DIQMTQSLSLSVSVGDRVTTCRASQGISNYLNWYQQK
PGKAPKPLIYYTSNLQSGVPSRFSGSGSGTDYTLTSSLQ
PEDFATYCMGQTISYTFGQGTKLEIK (SEQ ID NO: 1)
(5) Single-stranded heavy chain variable region (VH) sequence derived from BCMA-20 antibody:
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNFDMWVRQ
APGKGLVWVSSITTGADHAIYADSVKGRFTISRDNAKNTL
YLQMNSLRAEDTAVYYCVRHGYYDGYHLFDYWGQGTLVTV
SS (SEQ ID NO: 2)
(6) Single-stranded light chain variable region (VL) sequence derived from BCMA-CA8 antibody:
DIQLTQTTSSLSASSLSLGDRVTISCSATTSNYLNWYQQK
PDGTVELVIYYTSNLHGGGGPSRFSGSGSGTDYSLTYLE
PEDVATYYCQQYRKLPWTFGGGSKLEIKR (SEQ ID NO: 3)
(7) Single-stranded heavy chain variable region (VH) sequence derived from BCMA-CA8 antibody:
EVQLQQSGAVLARPGASVKMSCKGSGYTFTNYWMHWVKQ
RPGQGLEWIGATYRGHSDTYYNQKFKGKAKLTAVTSSTA
YMELSLTNEDSAVYYCTRGAIYNGYDVLDNWGQGTLVTV
SS (SEQ ID NO: 4)
(8)BCMA-MO6抗体由来の一本鎖の軽鎖可変領域(VL)配列:
DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQK
PGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFTLTISSLQ
PEDFATYYCQQYRKLPWTFGQGTKLEIKR (配列番号5)
(9)BCMA-MO6抗体由来の一本鎖の重鎖可変領域(VH)配列:
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQ
APGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTSTA
YMELSSLRSEDTAVYYCARGAIYDGYDVLDNWGQGTLVTV
SS (配列番号6)
(10)BCMA-1の一本鎖可変領域の重鎖と軽鎖の間の連結配列:
GSTSGSGKPGSGEGSTKG (配列番号10)
(11)BCMA-20、BCMA-CA8、BCMA-MO6の一本鎖可変領域の重
鎖と軽鎖の間の連結配列:
GGGGSGGGGSGGGGS (配列番号11)
(8) Single-stranded light chain variable region (VL) sequence derived from BCMA-MO6 antibody:
DIQMTQSLSLSVSVGDRVTTCSASSQDISNYLNWYQQK
PGKAPKLLIYYTSNLHSGVPSRFSGSGSGTDFSSLQ
PEDFATYYCQQYRKLPWTFGQGTKLEIKR (SEQ ID NO: 5)
(9) Single-stranded heavy chain variable region (VH) sequence derived from BCMA-MO6 antibody:
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSNYWMHWVRQ
APGQGLEWMGATYRGHSDTYYNQKFKGRVTITADKSTTA
YMELSSLRSEDITAVYYCARCAIYDGYDVLDNWGQGTLVTV
SS (SEQ ID NO: 6)
(10) Linkage sequence between heavy chain and light chain of single chain variable region of BCMA-1:
GSTSGSGGKPGSGESTKG (SEQ ID NO: 10)
(11) Linkage sequence between heavy chain and light chain of single chain variable region of BCMA-20, BCMA-CA8, BCMA-MO6:
GGGGSGGGGGSGGGGS (SEQ ID NO: 11)
(12)ヒンジ領域および連結領域の配列:
FVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEACRP
AAGGAVHTRGLDFACD (配列番号12)
(13)膜貫通領域であるCD8(CD8TM)抗原の膜貫通配列:
IYIWAPLAGTCGVLLLSLVITLYC (配列番号13)
(14)共刺激因子シグナル領域である4-1BB由来の細胞内シグナル伝達モチーフ
の配列:
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGG
CEL (配列番号14)
(15)CD3ζシグナル伝達領域であるTCR複合体におけるCD3ζの免疫受容体
チロシン活性化モチーフ(immunorecceptor tyrosine-based activation motif、ITA
M)の配列:
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRR
GRDPEMGGKPQRRKNPQEGLYNELQKDKMAEAYSEIGMKG
ERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (配列番号
15)
(12) Arrangement of hinge region and connecting region:
FVPVLPAKPTTPAPRPPTPAPTIASQPLSLRPEACRP
AAGGAVHTRGLDFACD (SEQ ID NO: 12)
(13) Transmembrane sequence of CD8 (CD8TM) antigen, which is a transmembrane region:
IYIWAPLAGTCGVLLLSLVITLYC (SEQ ID NO: 13)
(14) Sequence of intracellular signal transduction motif derived from 4-1BB, which is a co-stimulator signal region:
KRGRKKLLYIFKQPMRPVQTTQEEDGCSCRFPEEEEGG
CEL (SEQ ID NO: 14)
(15) CD3ζ immunoreceptor tyrosine-based activation motif (ITA) in the TCR complex, which is a CD3ζ signal transduction region.
Array of M):
RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRR
GRDPEMGGKPQRRKNPQEGLYNELQKDKMEAYSEIGMKG
ERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO: 15)
キメラ抗原受容体T細胞(CAR-T細胞)
本明細書で用いられるように、用語「CAR-T細胞」、「CAR-T」、「CART
」、「本発明のCAR-T細胞」とはいずれも本発明の第二の側面に記載のCAR-T細
胞である。
本発明は、BCMAを標的とするキメラ抗原受容体の構造の構築、BCMAを標的とす
るキメラ抗原受容体の遺伝子改変T細胞の製造方法およびその活性同定に関する。
Chimeric antigen receptor T cells (CAR-T cells)
As used herein, the terms "CAR-T cells", "CAR-T", "CART".
, And "CAR-T cells of the present invention" are both CAR-T cells according to the second aspect of the present invention.
The present invention relates to the construction of a structure of a chimeric antigen receptor targeting BCMA, a method for producing a genetically modified T cell of a chimeric antigen receptor targeting BCMA, and identification of its activity.
ベクター
所期の分子をコードする核酸配列は本分野で既知の組み換え方法、たとえば遺伝子を発
現する細胞においてライブラリーをスクリーニングすること、既知の当該遺伝子を含むベ
クターから当該ベクターを得ること、あるいは標準の技術で当該遺伝子を含む細胞および
組織から直接単離することによって得ることができる。必要により、興味のある遺伝子は
合成によって生産することもできる。
また、本発明は本発明の発現カセットが挿入されたベクターを提供する。レトロウイル
ス、たとえばレンチウイルス由来のベクターは、導入された遺伝子の長期間で、安定した
組み込みおよびその子細胞における増殖を可能にするため、長期間の遺伝子の移動を実現
させる適切な道具である。レンチウイルスは、増殖しない細胞、たとえば肝細胞に導入す
ることができるため、発癌性レトロウイルス、たとえばマウス白血病ウイルスのベクター
を超える利点を持つ。また、低免疫原性という利点もある。
Nucleic acid sequences encoding the desired molecules are recombinant methods known in the art, such as screening the library in cells expressing the gene, obtaining the vector from a known vector containing the gene, or standard. It can be obtained by technique by directly isolating from cells and tissues containing the gene. If desired, the gene of interest can also be produced synthetically.
The present invention also provides a vector into which the expression cassette of the present invention is inserted. Vectors derived from retroviruses, such as lentiviruses, are suitable tools for long-term gene migration, as they allow for long-term stable integration of the introduced gene and proliferation in its offspring. Lentiviruses have advantages over vectors of carcinogenic retroviruses such as murine leukemia virus because they can be introduced into non-proliferating cells such as hepatocytes. It also has the advantage of low immunogenicity.
簡単に要約すると、通常、本発明の発現カセットまたは核酸配列を操作可能にプロモー
ターに連結し、そしてそれを発現ベクターに組み込む。当該ベクターは、真核細胞の複製
および組み込みに適する。典型的なクローニングベクターは、所期の核酸配列の発現を調
節するのに使用できる転写と翻訳のターミネーター、開始配列およびプロモーターを含む
。
本発明の発現構築体は標準の遺伝子送達プロトコールによって、核酸免疫および遺伝子
療法に使用することもできる。遺伝子送達の方法は、本分野では既知である。たとえば、
米国特許番号5,399,346、5,580,859、5,589,466を参照し、
ここで引用によって全文を取り込む。もう一つの実施形態において、本発明は、遺伝子療
法ベクターを提供する。
Briefly summarized, the expression cassette or nucleic acid sequence of the invention is usually operably linked to a promoter and incorporated into an expression vector. The vector is suitable for eukaryotic cell replication and integration. Typical cloning vectors include transcriptional and translational terminators, initiation sequences and promoters that can be used to regulate the expression of the desired nucleic acid sequence.
The expression constructs of the invention can also be used for nucleic acid immunity and gene therapy by means of standard gene delivery protocols. Methods of gene delivery are known in the art. for example,
See U.S. Pat. No. 5,399,346,5,580,859,5,589,466.
Here, the full text is taken in by quoting. In another embodiment, the invention provides a gene therapy vector.
当該核酸は様々な種類のベクターにクローニンすることができる。たとえば、当該核酸
がクローニングできるベクターは、プラスミド、ファージ、ファージ誘導体、動物ウイル
スやコスミドを含むが、これらに限定されない。特定の興味のあるベクターは、発現ベク
ター、複製ベクター、プローブ生成ベクターおよびシークエンシングベクターを含む。
さらに、発現ベクターはウイルスベクターの形態によって細胞に提供することができる
。ウイルスベクターの技術は本分野公知のもので、そしてたとえばSambrookら(2001, Mo
lecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York)
およびほかのウイルス学と分子生物学のマニュアルに記載されている。ベクターとして使
用できるウイルスは、レトロウイルス、アデノウイルス、アデノ随伴ウイルス、ヘルペス
ウイルスやレンチウイルスを含むが、これらに限定されない。通常、適切なベクターは少
なくとも1種類の有機体において作用する複製開始点、プロモーター配列、便利な制限酵
素切断部位および1つまたは複数の選択できるマーカーを含む(たとえば、WO01/9
6584、WO01/29058および米国特許番号6,326,193)。
The nucleic acid can be cloninized into various types of vectors. For example, vectors in which the nucleic acid can be cloned include, but are not limited to, plasmids, phages, phage derivatives, animal viruses and cosmids. Certain vectors of interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors.
In addition, expression vectors can be provided to cells in the form of viral vectors. Viral vector techniques are well known in the art, and for example Sambrook et al. (2001, Mo).
lecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York)
And other virology and molecular biology manuals. Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpesviruses and lentiviruses. Suitable vectors usually include replication origins, promoter sequences, convenient restriction enzyme cleavage sites and one or more selectable markers that act on at least one organism (eg, WO01 / 9).
6584, WO 01/29058 and US Pat. No. 6,326,193).
すでに多くのウイルスに基づいたシステムが開発され、哺乳動物細胞への遺伝子の導入
に使用されている。たとえば、レトロウイルスは、遺伝子送達システムのための便利なプ
ラットホームを提供する。本分野で既知の技術によって選択された遺伝子をベクターに挿
入してレトロウイルス顆粒にパッケージングすることができる。当該組み換えウイルスは
、さらに分離されて体内または体外の対象細胞に送達される。多くのレトロウイルスシス
テムは本分野では既知である。一部の実施形態において、アデノウイルスベクターが使用
される。多くのアデノウイルスベクターは本分野では既知である。一部の実施形態におい
て、レンチウイルスベクターが使用される。
Many virus-based systems have already been developed and used to introduce genes into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. Genes selected by techniques known in the art can be inserted into vectors and packaged in retrovirus granules. The recombinant virus is further isolated and delivered to target cells in or out of the body. Many retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Many adenoviral vectors are known in the art. In some embodiments, lentiviral vectors are used.
付加のプロモーターエレメント、たとえばエンハンサーは転写が開始する頻度を調節す
ることができる。通常、これらは開始点の上流の30~110bpの領域に位置するが、
最近、多くのプロモーターは開始点の下流の機能エレメントも含むことが明らかになった
。プロモーターエレメントの間の間隔は、エレメントが別のエレメントに対して逆さまに
なったか、移動した場合、プロモーターの機能が維持できるように、可動性のものが多い
。チミジンキナーゼ(tk)プロモーターにおいて、プロモーターエレメントの間の間隔
は、活性が低下することなく、50bpまで増加することができる。プロモーターによっ
て、単一のエレメントは共同にまたは独立に作用し、転写を開始させる。
Additional promoter elements, such as enhancers, can regulate the frequency with which transcription begins. Normally, they are located in the region 30-110 bp upstream of the starting point,
Recently, it has been revealed that many promoters also contain functional elements downstream of the starting point. The spacing between promoter elements is often mobile so that if an element is turned upside down or moved with respect to another element, the promoter's function can be maintained. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased up to 50 bp without diminished activity. By the promoter, a single element acts jointly or independently to initiate transcription.
適切なプロモーターの一例は、前初期サイトメガロウイルス(CMV)プロモーター配
列である。当該プロモーター配列は操作可能にそれに連結した任意のポリヌクレオチド配
列を高レベルで発現させることができる強力な構成型プロモーター配列である。適切なプ
ロモーターのもう一例は、伸長因子1α(EF-1α)である。しかし、ほかの構成型プ
ロモーター配列を使用してもよく、シミアンウイルス40(SV40)初期プロモーター
、マウス乳癌ウイルス(MMTV)、ヒト免疫不全ウイルス(HIV)長鎖末端反復(L
TR)プロモーター、MoMuLVプロモーター、トリ白血病ウイルスプロモーター、エ
プスタイン・バール(Epstein-Barr)ウイルス前初期プロモーター、ラウス肉腫ウイルス
プロモーター、およびヒト遺伝子プロモーターを含むが、これらに限定されず、ヒト遺伝
子プロモーターは、たとえばアクチンプロモーター、ミオシンプロモーター、ヘムプロモ
ーターやクレアチンキナーゼプロモーターが挙げられるが、これらに限定されない。さら
に、本発明は構成型プロモーターの使用に限定されない。誘導型プロモーターも本発明の
一部として考えられる。誘導型プロモーターの使用は分子スイッチを提供し、それによっ
て、そのような発現が必要な場合、操作可能に誘導型プロモーターに連結したポリヌクレ
オチド配列の発現を開始させ、あるいは発現が必要ではない場合、発現を終止させること
ができる。誘導型プロモーターの例は、メタロチオネインプロモーター、糖質コルチコイ
ドプロモーター、プロゲステロンプロモーターやテトラサイクリンプロモーターを含むが
、これらに限定されない。
An example of a suitable promoter is the pre-early cytomegalovirus (CMV) promoter sequence. The promoter sequence is a potent constitutive promoter sequence capable of operably expressing any polynucleotide sequence linked to it at high levels. Another example of a suitable promoter is elongation factor 1α (EF-1α). However, other constitutive promoter sequences may be used, including the Simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), and human immunodeficiency virus (HIV) long-chain terminal repeats (L).
TR) promoters, MoMuLV promoters, trileukemia virus promoters, Epstein-Barr virus pre-early promoters, Raus sarcoma virus promoters, and human gene promoters, including, but not limited to, human gene promoters include, for example. Examples include, but are not limited to, the actin promoter, the myosin promoter, the hem promoter and the creatin kinase promoter. Moreover, the invention is not limited to the use of constitutive promoters. Inducible promoters are also considered as part of the present invention. The use of an inducible promoter provides a molecular switch, thereby initiating expression of a polynucleotide sequence operably linked to an inducible promoter if such expression is required, or if expression is not required. Expression can be terminated. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters and tetracycline promoters.
CARポリペプチドまたはその一部の発現を評価するため、細胞に導入された発現ベク
ターは選択できるマーカー遺伝子またはレポーター遺伝子のうちの任意の一方または両方
を含むようにすることによって、ウイルスベクターで形質導入または感染された細胞群か
ら発現細胞を同定および選択することもできる。また、選択できるマーカーは単独のDN
A断片に載せて共形質移入のプロセスに使用することができる。選択できるマーカー遺伝
子およびレポーター遺伝子の両者の隣接する領域には、いずれも適切な調節配列を有する
ことによって、宿主細胞において発現できるようにしてもよい。有用な選択できるマーカ
ーは、たとえば抗生物質耐性遺伝子、たとえばneoなどを含む。
To assess the expression of a CAR polypeptide or part thereof, the expression vector introduced into the cell is transduced with a viral vector by including any one or both of a selectable marker gene or reporter gene. Alternatively, expressing cells can be identified and selected from the infected cell population. In addition, the marker that can be selected is a single DN
It can be placed on the A fragment and used in the process of co-transfection. Adjacent regions of both the selectable marker gene and the reporter gene may have appropriate regulatory sequences so that they can be expressed in the host cell. Useful selectable markers include, for example, antibiotic resistance genes, such as neo.
レポーター遺伝子は形質導入された可能性のある細胞の同定および調節配列の機能性の
評価に使用される。通常、レポーター遺伝子は、レシピエントの有機体または組織に存在
しないか、レシピエントの有機体または組織によって発現され、そしてその発現が容易に
検出できる性質、たとえば酵素活性によって明確に示すことができるポリペプチドをコー
ドする遺伝子である。DNAがすでにレシピエントの細胞に導入されると、レポーター遺
伝子の発現は適切な時間で測定される。適切なレポーター遺伝子は、ルシフェラーゼ、β
-ガラクトシダーゼ、クロラムフェニコールアセチル基転移酵素、分泌型アルカリホスフ
ァターゼや緑色蛍光タンパク質をコードする遺伝子を含む(たとえば、Ui-Teiら,2000FE
BS Letters479:79-82)。適切な発現系は公知で、かつ既知の技術によって製造するか、
市販品として入手することができる。通常、最高レベルのレポーター遺伝子の発現を示す
、少なくとも5つのフランキング領域を有する構築体はプロモーターと同定される。この
ようなプロモーター領域はレポーター遺伝子に連結され、かつ試薬のプロモーターを調節
して転写を活性化させる能力の評価に使用することができる。
Reporter genes are used to identify cells that may have been transduced and to assess the functionality of regulatory sequences. Normally, a reporter gene is a poly that is not present in the recipient's organism or tissue, or is expressed by the recipient's organism or tissue, and its expression can be clearly demonstrated by a detectable property, such as enzymatic activity. It is a gene encoding a peptide. Once the DNA has already been introduced into the recipient's cells, the expression of the reporter gene is measured at the appropriate time. Suitable reporter genes are luciferase, β
-Contains genes encoding galactosidase, chloramphenicol acetyltransferase, secretory alkaline phosphatase and green fluorescent protein (eg, Ui-Tei et al., 2000FE).
BS Letters 479: 79-82). Suitable expression systems are known and manufactured by known techniques,
It can be obtained as a commercial product. Usually, constructs with at least 5 flanking regions showing the highest levels of expression of the reporter gene are identified as promoters. Such promoter regions are linked to the reporter gene and can be used to assess the ability of the reagent to regulate the promoter and activate transcription.
遺伝子を細胞に導入する方法および細胞において遺伝子を発現させる方法は、本分野で
は既知である。発現ベクターの内容において、ベクターは本分野における任意の方法によ
って宿主細胞、たとえば、哺乳動物、細菌、酵母や昆虫の細胞に容易に導入することがで
きる。たとえば、発現ベクターは物理、化学または生物学の手段によって宿主細胞に導入
することができる。
ポリヌクレオチドを宿主細胞に導入する物理的方法は、リン酸カルシウム沈殿、リポフ
ェクション、粒子衝突、マイクロインジェクション、エレクトロポレーションなどを含む
。ベクターおよび/または外来核酸を含む細胞を生産する方法は本分野では公知である。
たとえば、Sambrookら(2001, Molecular Cloning: A Laboratory Manual, Cold Spring
Harbor Laboratory, New York)を参照する。ポリヌクレオチドを宿主細胞に導入する好
適な方法は、リン酸カルシウム形質導入である。
Methods of introducing a gene into a cell and expressing the gene in the cell are known in the art. In the content of the expression vector, the vector can be readily introduced into host cells such as mammalian, bacterial, yeast and insect cells by any method in the art. For example, expression vectors can be introduced into host cells by physical, chemical or biological means.
Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, particle collisions, microinjection, electroporation and the like. Methods of producing cells containing vectors and / or foreign nucleic acids are known in the art.
For example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring)
Harbor Laboratory, New York). A preferred method for introducing a polynucleotide into a host cell is calcium phosphate transduction.
興味のあるポリヌクレオチドを宿主細胞に導入する生物学的方法は、DNAおよびRN
Aベクターを使用する方法を含む。ウイルスベクター、特にレトロウイルスベクターは、
すでに最も幅広く使用される、遺伝子を哺乳動物、たとえばヒト細胞に挿入する方法にな
っている。ほかのウイルスベクターはレンチウイルス、ポックスウイルス、単純ヘルペス
ウイルスI、アデノウイルスやアデノ随伴ウイルスなどからのものでもよい。例えば、米
国特許番号5,350,674および5,585,362を参照する。
ポリヌクレオチドを宿主細胞に導入する化学的手段は、コロイド分散系、たとえば大分
子複合体、ナノカプセル、マイクロスフェア、ビーズ、および水中油型乳剤、ミセル、混
合ミセル、やリポソームを含む脂質に基づいた系を含む。体外および体内の送達担体(de
livery vehicle)として使用される例示的なコロイド系はリポソーム(たとえば、人工膜
小胞)である。
Biological methods for introducing polynucleotides of interest into host cells include DNA and RN.
Includes a method using an A vector. Viral vectors, especially retroviral vectors,
It has already become the most widely used method of inserting genes into mammals, such as human cells. Other viral vectors may be from lentivirus, poxvirus, simple herpesvirus I, adenovirus, adeno-associated virus and the like. See, for example, US Pat. Nos. 5,350,674 and 5,585,362.
Chemical means of introducing polynucleotides into host cells were based on colloidal dispersions, such as large molecular complexes, nanocapsules, microspheres, beads, and lipids including oil-in-water emulsions, micelles, mixed micelles, and liposomes. Including system. In-vitro and in-vivo delivery carriers (de
An exemplary colloidal system used as a livery vehicle) is a liposome (eg, an artificial membrane vesicle).
非ウイルス送達系を使用する場合、例示的な送達担体はリポソームである。脂質製剤を
使用し、核酸を宿主細胞に導入することが考えられる(体外、エクスビボ(ex vivo)ま
たは体内)。また、当該核酸は脂質と関連してもよい。脂質と関連した核酸は、リポソー
ムの水性の内部に封入し、リポソームの脂質二重層に散在し、リポソームとオリゴヌクレ
オチドの両者に連結する連結分子を介してリポソームに接着し、リポソームに取り込まれ
、リポソームと複合体化し、脂質を含む溶液に分散し、脂質と混合し、脂質と配合し、懸
濁液として脂質に含まれ、ミセルに含まれるか、ミセルと複合体化し、あるいはほかの形
態で脂質と結合することができる。組成物と関連する脂質、脂質/DNAまたは脂質/発
現ベクターは溶液における具体的な構造のいずれにも限定されない。たとえば、二重層の
構造において、ミセルとして、または「崩壊した」構造で存在してもよい。簡単に溶液に
分散し、大きさや形状が異なる集合体を形成してもよい。脂質は脂肪物質で、天然の脂質
でも合成の脂質でもよい。たとえば、脂質は細胞質で自然に発生する脂肪小滴、ならびに
長鎖脂肪族炭化水素およびその誘導体、たとえば脂肪酸、アルコール類、アミン類、アミ
ノアルコール類やアルデヒド類のような化合物を含む。
本発明の一つの好適な実施形態において、前記ベクターはレンチウイルスベクターであ
る。
When using a non-viral delivery system, the exemplary delivery carrier is a liposome. It is conceivable to use a lipid preparation to introduce nucleic acid into a host cell (in vitro, ex vivo or in vivo). The nucleic acid may also be associated with lipids. Lipid-related nucleic acids are encapsulated inside the aqueous solution of the liposome, scattered in the lipid bilayer of the liposome, adhered to the liposome via a linking molecule that links to both the liposome and the oligonucleotide, incorporated into the liposome, and incorporated into the liposome. Complexes with lipids, disperses in lipid-containing solutions, mixes with lipids, blends with lipids, is contained in lipids as a suspension, is contained in micelles, is complexed with micelles, or in other forms lipids. Can be combined with. The lipid, lipid / DNA or lipid / expression vector associated with the composition is not limited to any of the specific structures in solution. For example, in a double layer structure, it may exist as a micelle or in a "collapsed" structure. It may be easily dispersed in a solution to form aggregates of different sizes and shapes. Lipids are fatty substances and may be natural or synthetic lipids. For example, lipids include naturally occurring lipid droplets in the cytoplasm, as well as long-chain aliphatic hydrocarbons and derivatives thereof, such as compounds such as fatty acids, alcohols, amines, aminoalcohols and aldehydes.
In one preferred embodiment of the invention, the vector is a lentiviral vector.
製剤
本発明は、本発明の第一の側面に記載のCAR-T細胞と、薬学的に許容される担体、
希釈剤または賦形剤とを含有する製剤を提供する。一つの実施形態において、前記製剤は
液体製剤である。好ましくは、前記製剤は注射剤である。好ましくは、前記製剤で、前記
CAR-T細胞の濃度が1×103~1×108細胞/mL、より好ましくは1×104
~1×107細胞/mLである。
一つの実施形態において、前記製剤は、緩衝液、たとえば中性緩衝食塩水、硫酸塩緩衝
食塩水など、炭水化物、たとえばブドウ糖、マンノース、ショ糖やデキストラン、マンニ
トール、タンパク質、ポリペプチドまたはアミノ酸、たとえばグリシン、酸化防止剤、キ
レート剤、たとえばEDTAやグルタチオン、アジュバント(たとえば、水酸化アルミニ
ウム)、および防腐剤を含んでもよい。本発明の製剤は、静脈内で施用するように調製す
ることが好ましい。
Pharmaceuticals The present invention comprises the CAR-T cells according to the first aspect of the present invention and a pharmaceutically acceptable carrier.
A pharmaceutical product containing a diluent or an excipient is provided. In one embodiment, the formulation is a liquid formulation. Preferably, the formulation is an injection. Preferably, in the above-mentioned preparation, the concentration of the CAR-T cells is 1 × 10 3 to 1 × 10 8 cells / mL, more preferably 1 × 10 4 .
~ 1 × 10 7 cells / mL.
In one embodiment, the formulation comprises buffers such as neutral buffered saline, sulfate buffered saline and other carbohydrates such as glucose, mannose, sucrose and dextran, mannitol, proteins, polypeptides or amino acids such as glycine. , Antioxidants, chelating agents such as EDTA and glutathione, adjuvants (eg aluminum hydroxide), and preservatives may be included. The pharmaceutical product of the present invention is preferably prepared for intravenous application.
治療的使用
本発明は、本発明の発現カセットをコードするレンチウイルスベクター(LV)で形質
導入された細胞(たとえば、T細胞)で行われる治療的使用を含む。形質導入された細胞
は、腫瘍細胞のマーカーであるBCMAを標的とし、協同してT細胞を活性化させ、T細
胞の免疫応答を引き起こすことによって、その腫瘍細胞に対する殺傷効率を顕著に向上さ
せることができる。
そのため、本発明は、哺乳動物の標的細胞群または組織に対するT細胞による免疫応答
を刺激する方法であって、哺乳動物に本発明のCAR-T細胞を施用する工程を含む方法
も提供する。
Therapeutic Use The present invention includes therapeutic use in cells transduced with a lentiviral vector (LV) encoding the expression cassette of the invention (eg, T cells). The transduced cells target BCMA, a marker of tumor cells, and cooperate to activate T cells and elicit an immune response of the T cells, thereby significantly improving the killing efficiency of the tumor cells. Can be done.
Therefore, the present invention also provides a method of stimulating an immune response by T cells to a target cell group or tissue of a mammal, which comprises a step of applying the CAR-T cells of the present invention to a mammal.
一つの実施形態において、本発明は、患者の自己T細胞(または異系ドナー)を分離し
、活性化させて遺伝子改変し、CAR-T細胞が生成した後、同患者の体内に注入する細
胞療法を含む。このような方法では、移植片対宿主病に罹る確率は極めて低く、抗原はT
細胞によってMHCに拘束されずに認識される。また、一つのCAR-Tで当該抗原を発
現するすべての癌を治療することができる。抗体療法と異なり、CAR-T細胞は体内で
複製可能で、持続的に腫瘍を抑える長期間の持久性が生じる。
一つの実施形態において、本発明のCAR-T細胞は安定した体内におけるT細胞の増
殖を経て延長した時間で持続することができる。また、CARによる免疫応答は養子免疫
療法の工程の一部でもよく、ここで、CAR修飾T細胞はCARにおける高原結合ドメイ
ンに特異的な免疫応答を誘導する。たとえば、抗BCMAのCAR-T細胞はBCMAを
発現する細胞に抵抗する特異的な免疫応答を引き起こす。
In one embodiment, the invention isolates a patient's autologous T cells (or allogeneic donors), activates and genetically modifies them to generate CAR-T cells, which are then injected into the patient's body. Including therapy. With such a method, the probability of getting graft-versus-host disease is extremely low, and the antigen is T.
Recognized by cells without being constrained by MHC. In addition, one CAR-T can treat all cancers expressing the antigen. Unlike antibody therapy, CAR-T cells are replicable in the body, resulting in long-term endurance that permanently suppresses tumors.
In one embodiment, the CAR-T cells of the invention can be sustained for an extended period of time through stable T cell proliferation in the body. The CAR immune response may also be part of the adoptive immunotherapy process, where CAR-modified T cells induce a plateau-binding domain-specific immune response in CAR. For example, anti-BCMA CAR-T cells elicit a specific immune response that resists BCMA-expressing cells.
本明細書で公開されたデータは、具体的に抗BCMA scFv、ヒンジおよび膜貫通
領域、および4-1BBとCD3ζシグナル伝達ドメインを含むレンチウイルスベクター
を公開したが、本発明は構築体の各構成部分の任意の数の変化を含むと解釈されるべきで
ある。
治療可能な癌は、血管新生がしていない腫瘍または血管新生が基本的にしていない腫瘍
、および血管新生がした腫瘍を含む。癌は、非固形腫瘍(たとえば血液腫瘍、たとえば白
血病やリンパ腫)または固形腫瘍を含んでもよい。本発明のCARで治療する癌の種類は
、癌、胚細胞腫瘍や肉腫、および一部の白血病やリンパ性悪性腫瘍、良性腫瘍および悪性
腫瘍、および悪性腫瘍、たとえば肉腫、癌やメラノーマを含むが、これらに限定されない
。成人腫瘍/癌および児童腫瘍/癌も含む。
The data published herein specifically publish a lentiviral vector containing an anti-BCMA scFv, a hinge and transmembrane domain, and a 4-1BB and CD3ζ signaling domain, whereas the present invention reveals each configuration of the construct. It should be construed to include any number of changes in the portion.
Treatable cancers include non-angiogenic or non-angiogenic tumors, and tumors with angiogenesis. The cancer may include a non-solid tumor (eg, a hematological tumor, such as leukemia or lymphoma) or a solid tumor. The types of cancer treated with CAR of the present invention include cancer, embryonic cell tumors and sarcoma, and some leukemia and lymphatic malignancies, benign and malignant tumors, and malignant tumors such as sarcoma, cancer and melanoma. , Not limited to these. Also includes adult tumors / cancers and childhood tumors / cancers.
血液癌は血液または骨髄の癌である。血液(または血液原性)癌の例は、白血病を含み
、それに急性白血病(たとえば急性リンパ性白血病、急性骨髄球性白血病、急性骨髄性白
血病および骨髄芽球性、前骨髄球性、骨髄単球型、単核球性や赤白血病)、慢性白血病(
たとえば慢性骨髄球性(顆粒球性)白血病、慢性骨髓性白血病や慢性リンパ性白血病)、
真性赤血球増加症、リンパ腫、ホジキン病、非ホジキンスリンパ腫(無痛および重症の場
合)、多発性骨髄腫、ワルデンシュトレーム型マクログロブリン血症、H鎖病、骨髄異形
成症候群、有毛細胞白血病や脊髄形成異常が含まれる。
固形腫瘍は、通常、嚢腫や液体領域の組織の腫瘤を含まない。固形腫瘍は良性でも悪性
でもよい。異なる種類の固形腫瘍はこれらを形成する細胞の種類によって命名される(た
とえば肉腫、癌やリンパ腫)。固形腫瘍は、たとえば肉腫および癌の例は、線維肉腫、粘
液肉腫、脂肪肉腫、中皮腫、リンパ性悪性腫瘍、膵臓癌、卵巣癌を含む。
Blood cancer is cancer of the blood or bone marrow. Examples of blood (or hematogenous) cancers include leukemia, which includes acute leukemia (eg, acute lymphocytic leukemia, acute myelocytic leukemia, acute myeloid leukemia and myeloblastic, promyelomonocytes, myelomonocytes). Type, mononuclear and red leukemia), chronic leukemia (
For example, chronic myelogenous (granulocytic) leukemia, chronic osteogenic leukemia and chronic lymphocytic leukemia),
True erythrocytosis, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma (painless and severe), multiple myeloma, Waldenström macroglobulinemia, H chain disease, myelodysplastic syndrome, hairy cell leukemia And spinal cord dysplasia.
Solid tumors usually do not include cysts or masses of tissue in the fluid area. Solid tumors can be benign or malignant. Different types of solid tumors are named by the type of cells that form them (eg, sarcoma, cancer or lymphoma). Solid tumors include, for example, sarcomas and cancer examples include fibrosarcoma, mucocele, liposarcoma, mesopharia, lymphocytic malignancies, pancreatic cancer, ovarian cancer.
本発明のCAR修飾T細胞は哺乳動物に対する体外免疫および/または体内療法のワク
チンとしても有用である。好ましくは、哺乳動物はヒトである。
体外免疫について、i)細胞の増殖、ii)CARをコードする核酸の細胞への導入、
および/またはiii)細胞の凍結保存のうちの少なくとも一つが細胞を哺乳動物に施用
する前に体外で行われる。
体外プロトコールは本分野では公知で、そして後記でより完全に検討される。簡単に言
えば、細胞を哺乳動物(好ましくはヒト)から単離して本明細書で公開されるCARを発
現するベクターで遺伝子修飾を行う(すなわち、体外形質転換または形質導入)。CAR
修飾細胞は哺乳動物のレシピエントに施用し、治療の有益な効果を提供することができる
。哺乳動物のレシピエントはヒトでもよく、そしてCAR修飾細胞はレシピエント自身の
細胞でもよい。必要により、細胞はレシピエントに対して同種異系、同系(syngeneic)
または異種でもよい。
体外免疫について細胞に基づいたワクチン以外、本発明は、体内免疫によって患者にお
ける抗原に対する免疫応答を引き起こす組成物および方法も提供する。
The CAR-modified T cells of the present invention are also useful as vaccines for in vitro immunization and / or in-vivo therapy against mammals. Preferably, the mammal is a human.
For in vitro immunity, i) cell proliferation, ii) introduction of CAR-encoding nucleic acids into cells,
And / or iii) At least one of the cryopreservation of cells is performed in vitro prior to application of the cells to mammals.
In vitro protocols are known in the art and will be considered more thoroughly later. Briefly, cells are isolated from mammals (preferably humans) and genetically modified with a CAR-expressing vector exposed herein (ie, in vitro transformation or transduction). CAR
Modified cells can be applied to mammalian recipients to provide beneficial therapeutic effects. The mammalian recipient may be human, and the CAR-modified cells may be the recipient's own cells. If necessary, the cells are allogeneic and syngeneic to the recipient.
Or it may be different.
In addition to cell-based vaccines for in vitro immunity, the invention also provides compositions and methods that elicit an immune response against an antigen in a patient by in vitro immunity.
本発明は、腫瘍を治療する方法であって、それが必要な対象に治療有効量の本発明のC
AR修飾T細胞を施用する工程を含む方法を提供する。
本発明のCAR修飾T細胞は単独で、または薬物組成物として希釈剤および/またはほ
かの成分、たとえばIL-2、IL-17やほかのサイトカインまたは細胞群と合わせて
施用することができる。簡単に言えば、本発明の薬物組成物は、本明細書に記載の標的細
胞群を含み、一つまたは複数の薬学または生理学的に許容される担体、希釈剤または賦形
剤と合わせてもよい。このような組成物は、緩衝液、たとえば中性緩衝食塩水、硫酸塩緩
衝食塩水など、炭水化物、たとえばブドウ糖、マンノース、ショ糖やデキストラン、マン
ニトール、タンパク質、ポリペプチドまたはアミノ酸、たとえばグリシン、酸化防止剤、
キレート剤、たとえばEDTAやグルタチオン、アジュバント(たとえば、水酸化アルミ
ニウム)、および防腐剤を含んでもよい。本発明の組成物は、静脈内で施用するように調
製することが好ましい。
The present invention is a method of treating a tumor, and a therapeutically effective amount of C of the present invention is applied to a subject in need thereof.
Provided is a method including a step of applying AR-modified T cells.
The CAR-modified T cells of the invention can be applied alone or as a drug composition in conjunction with diluents and / or other components such as IL-2, IL-17 and other cytokines or cell populations. Briefly, the drug compositions of the invention include the target cell populations described herein, even when combined with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. good. Such compositions include buffers such as neutral buffered saline, sulfate buffered saline and other carbohydrates such as glucose, mannose, sucrose and dextran, mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants. Agent,
It may contain a chelating agent such as EDTA or glutathione, an adjuvant (eg aluminum hydroxide), and a preservative. The compositions of the present invention are preferably prepared for intravenous application.
本発明の薬物組成物は、治療(または予防)が必要な疾患に適する形態によって施用す
ることができる。施用の数量および頻度は、患者の病床、および患者の疾患の種類と重篤
度のような要素によって決まるが、適切な投与量は臨床試験によって決定する。
「免疫学的な有効量」、「抗腫瘍有効量」、「腫瘍抑制有効量」または「治療量」と記
載する場合、施用される本発明の組成物の精確な量は、患者(対象)の年齢、体重、腫瘍
の大きさ、感染または転移の程度および病症の個体差を考慮し、医師によって決められる
。通常、本明細書に記載のT細胞を含む薬物組成物は、104~109個細胞/kg体重
の投与量、好ましくは105~106個細胞/kg体重の投与量(これらの範囲内におけ
るすべての整数値を含む)で施用することができる。T細胞の組成物はこれらの投与量で
数回施用してもよい。細胞は、免疫療法で公知の注入技術(たとえばRosenbergら,NewEn
g.J. of Med. 319:1676,1988)によって施用することができる。具体的な患者対する最適
な投与量および治療プランは、患者の疾患の所見をモニタリングしてそれに基づいて調整
して治療することができ、医学分野の技術者によって容易に決めることができる。
The drug composition of the present invention can be applied in a form suitable for a disease requiring treatment (or prevention). The quantity and frequency of application will depend on factors such as the patient's bed and the type and severity of the patient's disease, but the appropriate dose will be determined by clinical trials.
When described as "immunologically effective amount", "anti-tumor effective amount", "tumor-suppressing effective amount" or "therapeutic amount", the exact amount of the composition of the present invention to be applied is the patient (subject). Determined by the doctor, taking into account the age, weight, size of the tumor, degree of infection or metastasis, and individual differences in the disease. Generally, the T cell-containing drug compositions described herein have a dose of 104 to 109 cells / kg body weight, preferably a dose of 105 to 10 6 cells / kg body weight (range of these). Can be applied with (including all integer values within). The T cell composition may be applied several times at these doses. Cells are known for injection techniques in immunotherapy (eg Rosenberg et al., NewEn).
It can be applied by gJ of Med. 319: 1676, 1988). The optimal dosage and treatment plan for a specific patient can be monitored, adjusted and treated based on the patient's findings of the disease, and can be easily determined by a technician in the medical field.
対象への組成物の施用は噴霧法、注射、経口、輸液、植込みまたは移植を含む任意の便
利な手段によって行ってもよい。本明細書に記載の組成物は皮下、皮内、腫瘍内、節内、
脊髄内、筋肉内、静脈内(i.v.)注射または腹膜内で患者に施用されてもよい。一つ
の実施形態において、本発明のT細胞の組成物は皮内または皮下注射によって患者に施用
される。もう一つの実施形態において、本発明のT細胞の組成物はi.v.注射によって
施用することが好ましい。T細胞の組成物は直接腫瘍、リンパ節または感染の箇所に注入
してもよい。
Application of the composition to the subject may be by any convenient means, including spraying, injection, oral, infusion, implantation or transplantation. The compositions described herein are subcutaneous, intradermal, intratumoral, intranodes, and
It may be administered to the patient by intraspinal, intramuscular, intravenous (iv) injection or intraperitoneal. In one embodiment, the T cell compositions of the invention are applied to a patient by intradermal or subcutaneous injection. In another embodiment, the T cell composition of the present invention is i. v. It is preferably applied by injection. The composition of T cells may be injected directly into the tumor, lymph node or site of infection.
本発明の一部の実施形態において、本明細書に記載の方法または本分野で既知のほかの
T細胞を治療的レベルに増殖させる方法によって活性化および増殖した細胞を使用し、任
意の数量の関連治療手段と合わせて(たとえば、その前、同時またはその後に)患者に施
用し、前記治療手段は、抗ウイルス療法、シドフォビルおよびインターロイキン-2、ア
ザシチジン(ARA-Cとして知られる)のような試薬で治療するもの、あるいはMS患
者に対するナタリズマブによる治療または乾癬患者に対するエファリズマブによる治療ま
たはPML患者に対するほかの治療を含むが、これらに限定されない。さらなる実施形態
において、本発明のT細胞は、化学治療、放射線、免疫抑制剤、たとえばシクロスポリン
A、アザチオプリン、メトトレキセート、ミコフェノール酸モフェチルやFK506、抗
体またはほかの免疫治療剤と併用することができる。さらなる実施形態において、本発明
の細胞組成物は、骨髄移植、化学治療剤、たとえばフルダラビン、外部光線放射線療法(
XRT)、シクロホスファミドと併用して(たとえば、その前、同時またはその後に)患
者に施用する。たとえば、一つの実施形態において、対象は高投与量の化学治療の後、末
梢血幹細胞移植してもよい。一部の実施形態において、移植後、対象は本発明の増殖した
免疫細胞の注入を受ける。別の一つの実施形態において、増殖した細胞は外科手術前また
は外科手術後に施用される。
In some embodiments of the invention, any quantity of cells activated and proliferated by the methods described herein or by proliferating other T cells known in the art to therapeutic levels is used. When applied to a patient in combination with related treatments (eg, prior, simultaneous or subsequent), said treatments such as antiviral therapy, Sidphovir and Interleukin-2, azacitidine (known as ARA-C). It includes, but is not limited to, treatment with reagents, or treatment with natalizumab for MS patients, efarizumab treatment for psoriasis patients, or other treatments for PML patients. In a further embodiment, the T cells of the invention can be used in combination with chemotherapeutic, radiation, immunosuppressive agents such as cyclosporine A, azathioprine, methotrexate, mycophenolate mofetil and FK506, antibodies or other immunotherapeutic agents. In a further embodiment, the cell compositions of the invention are bone marrow transplants, chemotherapeutic agents such as fludarabine, external photoradiation therapy (
XRT), administered to patients in combination with cyclophosphamide (eg, before, at the same time or after). For example, in one embodiment, the subject may be transplanted with peripheral blood stem cells after high dose chemotherapy. In some embodiments, after transplantation, the subject receives an injection of proliferated immune cells of the invention. In another embodiment, the proliferated cells are applied before or after surgery.
患者に施用する以上の治療の投与量は治療する病症の精確な属性および治療するレシピ
エントによって変わる。患者へ施用する投与量の比率は本分野で許容される実践によって
実施することができる。通常、1回の治療または1回の治療クールに、1×106個~1
×1010個の本発明の修飾されたT細胞(たとえば、CAR-T-BCMA細胞)を、
たとえば静脈輸液の手段によって、患者に施用することができる。
The dosage of more treatment than applied to the patient depends on the exact attributes of the disease to be treated and the recipient to be treated. The proportion of dose applied to the patient can be carried out by practices acceptable in the art. Usually 1 x 10 6 to 1 per treatment or one treatment course
× 10 10 modified T cells of the invention (eg, CAR-T-BCMA cells).
It can be applied to a patient, for example, by means of intravenous infusion.
本発明の主な利点は以下の通りである。
(a)本発明のキメラ抗原受容体は、細胞外抗原結合ドメインが特定の抗BCMA s
cFvで、当該特定の抗BCMA scFvは特定のヒンジ領域および細胞内ドメインと
結合してなるCARは非常に強力な腫瘍細胞に対する殺傷能力を示し、しかも細胞毒性が
小さく、副作用が低い。
(b)本発明によって提供されるキメラ抗原受容体はCAR遺伝子を担持するレンチウ
イルスでT細胞を感染させた後、CARタンパク質の安定した発現および膜局在化を実現
することができる。
(c)本発明のCAR修飾T細胞は体内で生存時間が長く、かつ抗湯用効果が強く、本
発明で使用されるscFvはヒト化抗体またはヒト由来の抗体で、特異的な免疫拒絶反応
が生じる可能性が小さい。
The main advantages of the present invention are as follows.
(A) The chimeric antigen receptor of the present invention has an anti-BCMA s having a specific extracellular antigen-binding domain.
In cFv, the particular anti-BCMA scFv is bound to a particular hinge region and intracellular domain, and CAR exhibits a very strong ability to kill tumor cells, yet has low cytotoxicity and low side effects.
(B) The chimeric antigen receptor provided by the present invention can realize stable expression and membrane localization of CAR protein after infecting T cells with a lentivirus carrying a CAR gene.
(C) The CAR-modified T cells of the present invention have a long survival time in the body and have a strong anti-hot water effect, and the scFv used in the present invention is a humanized antibody or a human-derived antibody, which is a specific immune rejection reaction. Is unlikely to occur.
以下、具体的な実施例によって、さらに本発明を説明する。これらの実施例は本発明を
説明するために用いられるものだけで、本発明の範囲の制限にはならないと理解されるも
のである。以下の実施例で具体的な条件が示されていない実験方法は、通常、たとえばSa
mbrookら、「モレキュラー・クローニング:研究室マニュアル」(ニューヨーク、コール
ド・スプリング・ハーバー研究所出版社、1989)に記載の条件などの通常の条件に、
あるいは、メーカーのお薦めの条件に従う。特に断らない限り、%と部は、重量で計算さ
れた。
Hereinafter, the present invention will be further described with reference to specific examples. It is understood that these examples are used only to illustrate the invention and do not limit the scope of the invention. Experimental methods for which specific conditions are not shown in the following examples are usually, for example, Sa.
Under normal conditions, such as those described in "Molecular Cloning: Laboratory Manual" (New York, Cold Spring Harbor Laboratory Publishing Co., Ltd., 1989), mbrook et al.
Alternatively, follow the manufacturer's recommended conditions. Unless otherwise noted,% and parts were calculated by weight.
実施例1
レンチウイルス発現ベクターの構築
コードプラスミドの構築は、上海博益生物科技有限公司に全長DNAの合成およびクロ
ーンを依頼し、実現させた。pWPTレンチウイルスベクターをクローニングベクターと
し、クローニング部位はBamH IおよびSal I部位である。具体的な配列は前記
の通りである。
Example 1
Construction of Lentivirus Expression Vector The construction of the code plasmid was realized by requesting Shanghai Hakuei Biotechnology Co., Ltd. to synthesize and clone full-length DNA. The pWPT lentiviral vector is used as the cloning vector, and the cloning sites are BamHI and Sal I sites. The specific arrangement is as described above.
実施例2
CAR-T細胞の製造
(1)健常者の静脉血を採取し、密度勾配遠心法によって単核球を単離した(PBMC
s)。
(2)0日目に、PBMCsを事前に最終濃度が5μg/mLのCD3モノクローナル
抗体(OKT3)および最終濃度が10μg/mLのRetronectin(TAKARA社から購入)
でコーティングした細胞培養瓶に接種し、培地は1%ヒト血清アルブミン含有GT-T5
51細胞培地で、培地に最終濃度が1000U/mLになるように組み換えヒトインター
ロイキン-2(IL-2)を添加し、37℃、飽和湿度、5% CO2のインキュベータ
ーで培養した。
Example 2
Production of CAR-T cells (1) Static blood of healthy subjects was collected and mononuclear cells were isolated by density gradient centrifugation (PBMC).
s).
(2) On
Inoculate into cell culture bottles coated with 1% human serum albumin-containing GT-T5 medium.
In 51 cell medium, recombinant human interleukin-2 (IL-2) was added to the medium to a final concentration of 1000 U / mL, and the cells were cultured in an incubator at 37 ° C., saturated humidity and 5% CO 2 .
(3)1日目に、ゆっくりPBMCsを培養する上清液を吸い取って捨て、そして新し
い1%ヒト血清アルブミン含有GT-T551細胞培地を入れ、培地に最終濃度が100
0U/mLになるように組み換えヒトインターロイキン-2(IL-2)を入れ、37℃
、飽和湿度、5% CO2のインキュベーターで培養した。
(4)3日目に、新鮮な培養液、濃縮・精製されたCAR-BCMAsレンチウイルス
液、プロタミン硫酸塩(12μg/ml)、および最終濃度が1000U/mLのIL-
2を入れた。37℃、5% CO2のインキュベーターで12時間感染させた後、培養液
を捨て、新鮮な培地を入れ、37℃、5% CO2のインキュベーターで培養を続けた。
(5)6日目から、CART-BCMAs細胞を取って相応する活性検出試験を行うこ
とができた。
(3) On the first day, the supernatant for slowly culturing PBMCs is sucked up and discarded, and a new GT-T551 cell medium containing 1% human serum albumin is added, and the final concentration is 100 in the medium.
Add recombinant human interleukin-2 (IL-2) to 0 U / mL and add 37 ° C.
Incubators with saturated humidity, 5% CO 2 and incubators.
(4) On the third day, fresh culture solution, concentrated and purified CAR-BCMAs lentivirus solution, protamine sulfate (12 μg / ml), and IL- with a final concentration of 1000 U / mL.
I put in 2. After infection in an incubator at 37 ° C. and 5% CO 2 for 12 hours, the culture medium was discarded, fresh medium was added, and the culture was continued in the incubator at 37 ° C. and 5% CO 2 .
(5) From the 6th day, CART-BCMAs cells could be taken and a corresponding activity detection test could be performed.
実施例3
CAR遺伝子のT細胞ゲノムにおける組み込み率およびそれによってコードされるタン
パク質の膜表面における発現レベルの検出
それぞれ0.5×106の実施例2で7日目(図3A)、21日目(図3B)および2
9日目(図3C)まで培養したCART-BCMAs細胞のサンプルを取り、組み換えヒ
トBCMAタンパク質のFc断片で染色した後、フローサイトメーターによってCAR-
BCMAタンパク質のT細胞の膜表面における発現レベルを分析した。
結果は図3に示すように、本発明で設計された4つのCAR構造はいずれもその相応す
る修飾T細胞で発現され、そして細胞膜表面における局在化が完成した。
Example 3
Detection of the rate of integration of the CAR gene in the T cell genome and the expression level of the protein encoded by it on the membrane surface in Example 2 of 0.5 × 106 on days 7 (3A) and 21 (3B, respectively). ) And 2
A sample of CART-BCMAs cells cultured up to day 9 (FIG. 3C) was taken, stained with an Fc fragment of recombinant human BCMA protein, and then CAR- by a flow cytometer.
The expression level of BCMA protein on the membrane surface of T cells was analyzed.
As a result, as shown in FIG. 3, all four CAR structures designed in the present invention were expressed in their corresponding modified T cells, and localization on the cell membrane surface was completed.
実施例4
CART-BCMAsの体外活性化能力の検出
実施例2における7日目まで培養されたCART-BCMAs細胞で細胞の活性化レベ
ル指標であるタンパク質CD137およびIFNγの検出を行った。順に7日目まで培養
したCART-BCMA細胞を1×105個取り、それぞれBCMA陽性のK562-B
CMA+E7腫瘍細胞系、ならびにBCMA陰性のK562腫瘍細胞系と、あるいは腫瘍
細胞を添加せずに、200μlのGT-551培地において1:1の比率で18h培養し
た後、フローサイトメトリーによってT細胞の膜表面おけるCD137の発現レベルを、
ELISA方法によって培養上清におけるIFNγの分泌レベルを検出した。
結果は図4Aおよび図4Bに示すように、4つのCART細胞の表面はいずれもCD1
37の発現が検出され、かついずれも培養上清にIFNγの発現が検出された。中では、
CAR-BCMA-20は最も優れたCD137活性化レベルおよびIFNγ放出レベル
を有し、ヒト化MO6抗体配列に基づいて構築されたCART-BCMA-MO6はネズ
ミ由来抗体配列に基づいて構築されたCART-BCMA-CA8と比べて弱いCD13
7活性化レベルを有するが、高いIFNγ放出レベルを有する。
Example 4
Detection of in vitro activation ability of CART-BCMAs In CART-BCMAs cells cultured up to the 7th day in Example 2, proteins CD137 and IFNγ, which are indicators of cell activation level, were detected. 1 × 10 5 CART-BCMA cells cultured up to the 7th day were taken in order, and each was BCMA-positive K562-B.
CMA + E7 tumor cell line and BCMA-negative K562 tumor cell line, or without tumor cells added, cultured in 200 μl GT-551 medium at a ratio of 1: 1 for 18 hours, and then the membrane of T cells by flow cytometry. The expression level of CD137 on the surface,
The level of IFNγ secretion in the culture supernatant was detected by the ELISA method.
The results are shown in FIGS. 4A and 4B, where the surfaces of all four CART cells are all CD1.
The expression of 37 was detected, and the expression of IFNγ was detected in the culture supernatant in each case. Inside
CAR-BCMA-20 has the best CD137 activation and IFNγ release levels, and CART-BCMA-MO6 constructed based on the humanized MO6 antibody sequence is based on the murine-derived antibody sequence CART- CD13 weaker than BCMA-CA8
It has 7 activation levels but high IFNγ release levels.
実施例5
CART-BCMAs細胞による腫瘍細胞の末期アポトーシスの誘導活性の検出
(1)1:1、2.5:1、5:1、10:1、20:1の比率(図5に示される比率
)で、それぞれ実施例2における17日目まで培養されたCART-BCMAs細胞を1
×104個のCFSEで標識されたBCMA陰性細胞(NH929)またはBCMA陽性
の構築された細胞NH929-BCMA過剰発現腫瘍細胞株と混合し、100μlのGT
-551培地において4h共培養した後、100μlの25%PI色素で15min染色
し、フローサイトメーターによってCFSE陽性細胞におけるPI陽性細胞の比率を分析
した。
(2)1:1、5:1、10:1、20:1、40:1の比率(図6Bに示される比率
)で、それぞれ実施例2における22日目まで培養されたCART-BCMAs細胞を1
×104個のCFSEで標識されたBCMA陰性細胞(NH929)、BCMA陽性の構
築された細胞NH929-BCMA過剰発現腫瘍細胞株、または天然のBCMAを発現す
るMM.1S細胞系と混合し、100μlのGT-551培地において4h共培養した後
、100μlの25%PI色素で15min染色し、フローサイトメーターによってCF
SE陽性細胞におけるPI陽性細胞の比率を分析した。
結果は図5および図6に示すように、4つのCART細胞はいずれも好適にBCMA陽
性腫瘍細胞のアポトーシスを誘導することができた。中では、CART-BCMA-20
はCART-BCMA-1よりも好適にBCMA陽性腫瘍細胞の末期アポトーシスを誘導
し、CART-BCMA-MO6およびCART-BCMA-CA8はBCMA陽性腫瘍
細胞の末期アポトーシスを誘導する能力が類似する。
Example 5
Detection of end-stage apoptosis-inducing activity of tumor cells by CART-BCMAs cells (1) 1: 1, 2.5: 1, 5: 1, 10: 1, 20: 1 ratio (ratio shown in FIG. 5) , CART-BCMAs cells cultured up to the 17th day in Example 2, respectively.
× 10 100 μl GT mixed with 4 CFSE-labeled BCMA-negative cells (NH929) or BCMA-positive constructed cells NH929-BCMA overexpressing tumor cell lines.
After co-culturing in -551 medium for 4 hours, the cells were stained with 100 μl of 25% PI dye for 15 min, and the ratio of PI-positive cells to CFSE-positive cells was analyzed by a flow cytometer.
(2) CART-BCMAs cells cultured up to day 22 in Example 2 at a ratio of 1: 1, 5: 1, 10: 1, 20: 1, 40: 1 (ratio shown in FIG. 6B), respectively. 1
× 10 BCSE -labeled BCMA-negative cells (NH929), BCMA-positive constructed cells NH929-BCMA overexpressing tumor cell lines, or MM expressing native BCMA. It was mixed with a 1S cell line, co-cultured in 100 μl of GT-551 medium for 4 hours, stained with 100 μl of 25% PI dye for 15 min, and CFed by a flow cytometer.
The ratio of PI-positive cells to SE-positive cells was analyzed.
As a result, as shown in FIGS. 5 and 6, all four CART cells were able to suitably induce apoptosis of BCMA-positive tumor cells. Among them, CART-BCMA-20
Better than CART-BCMA-1 to induce end-stage apoptosis of BCMA-positive tumor cells, and CART-BCMA-MO6 and CART-BCMA-CA8 have similar abilities to induce end-stage apoptosis of BCMA-positive tumor cells.
実施例6
CART-BCMAsのRPMI-8226骨髄腫異種移植モデルに対する抑制作用
対数増殖期にあるRPMI-8226細胞を収集し、6-8週のB-NDGマウスの右
側背部に4.0×106個の腫瘍細胞を皮下接種し、腫瘍体積が120mm3程度に達し
た時点で、動物を腫瘍体積によってランダムに4群に各群の腫瘍体積の違いが平均値の1
0%よりも小さいように分けた後、それぞれ尾静脈から溶媒対照、7.5×106個のN
Tおよび7.5×106個のCART-BCMAs細胞を注射した。
結果は図7に示すように、対照群と比べ、CART-BCMA-1およびCART-B
CMA-20の単回の尾静脈注射は、有効にヒト骨髄腫RPMI-8226細胞の生長を
抑制し(相対腫瘍増殖率%T/CRTV≦40%、P<0.05)、かつ顕著にヒト骨髄
腫担持マウスの生存時間を延ばし(対照群で生存期間が23日で、CART-BCMAs
治療群で生存期間の中央値>33日)、中では、CART-BCMA-1およびCART
-BCMA-20による治療を受けたマウスは、相対腫瘍増殖率および生存期間の中央値
に有意差がなかった。
Example 6
Suppressive effect of CART-BCMAs on RPMI-8226 xenograft model RPMI-8226 cells in logoproliferative phase were collected and 4.0 × 10 6 tumors on the right dorsal side of 6-8 week B-NDG mice. When the cells were subcutaneously inoculated and the tumor volume reached about 120 mm3 , the animals were randomly divided into 4 groups according to the tumor volume, and the difference in the tumor volume of each group was 1 of the average value.
After dividing into smaller than 0%, solvent control from the tail vein, 7.5 × 10 6 N
T and 7.5 × 10 6 CART-BCMAs cells were injected.
The results are shown in FIG. 7, as compared with the control group, CART-BCMA-1 and CART-B.
A single tail intravenous injection of CMA-20 effectively suppressed the growth of human myeloma RPMI-8226 cells (relative tumor growth rate% T / CRTV ≤ 40%, P <0.05) and was markedly human. Prolonged survival time of myeloma-carrying mice (23 days survival in control group, CART-BCMAs)
Median survival> 33 days in the treatment group), among which CART-BCMA-1 and CART
Mice treated with BCMA-20 had no significant difference in relative tumor growth and median survival.
比較例
本願のキメラ抗原受容体のスクリーニング過程中において、発明者らは大量の候補配列
をテストしたが、以下、例を挙げて説明する。
スクリーニングされた抗体は、BCMA-1、BCMA-2、BCMA-69、BCM
A-72、BCMA-2A1、BCMA-1E1、BCMA-J22.9、BCMA-2
0、BCMA-CA8、BCMA-MO6である。上記抗体に基づいて構築された、BC
MAを標的とするキメラ抗原受容体の構造である。ここで、BCMA-1およびBCMA
-2はすでに発表されたCar-T配列で、スクリーニングの陽性対照として、CAR-
T細胞の製造方法は実施例2と同様で、検出方法は実施例3、4と同様である。
結果は図1に示すように、それぞれ2ロットのCAR-T細胞の実施結果である。BC
MA-Fc融合タンパク質でCar-Tの発現を検出したところ、初代T細胞に高発現が
見られ、図1Aを参照する。図1Bにおいて、BCMA-1、BCMA-20、BCMA
-1E1、BCMA-CA8、BCMA-MO6、およびBCMA-J22.9はBCM
A抗原によって活性化されたことがわかる。図1Cでは、活性化されたBCMA-1、B
CMA-20、BCMA-1E1、BCMA-CA8、BCMA-MO6、およびBCM
A-J22.9のCar-Tは比較的に高いIFN-γを生成したことが示された。これ
らの結果をまとめると、BCMA-1、BCMA-20、CA8およびMO6で得られた
CAR-Tは機能が近いことが示されたため、BCMA-20、CA8およびMO6CA
R-Tをさらに分析し、研究した。
Comparative Example In the process of screening the chimeric antigen receptor of the present application, the inventors tested a large number of candidate sequences, which will be described below with an example.
The screened antibodies were BCMA-1, BCMA-2, BCMA-69, and BCM.
A-72, BCMA-2A1, BCMA-1E1, BCMA-J22.9, BCMA-2
0, BCMA-CA8, BCMA-MO6. BC constructed based on the above antibody
It is the structure of a chimeric antigen receptor that targets MA. Here, BCMA-1 and BCMA
-2 is a previously published Car-T sequence, and CAR- is a positive control for screening.
The method for producing T cells is the same as in Example 2, and the detection method is the same as in Examples 3 and 4.
The results are the results of performing 2 lots of CAR-T cells, respectively, as shown in FIG. BC
When the expression of Car-T was detected in the MA-Fc fusion protein, high expression was observed in the primary T cells, which is referred to in FIG. 1A. In FIG. 1B, BCMA-1, BCMA-20, BCMA.
-1E1, BCMA-CA8, BCMA-MO6, and BCMA-J22.9 are BCM
It can be seen that it was activated by the A antigen. In FIG. 1C, activated BCMA-1, B
CMA-20, BCMA-1E1, BCMA-CA8, BCMA-MO6, and BCM
It was shown that Car-T of A-J22.9 produced relatively high IFN-γ. Summarizing these results, the CAR-Ts obtained with BCMA-1, BCMA-20, CA8 and MO6 were shown to have similar functions, so BCMA-20, CA8 and MO6CA.
RT was further analyzed and studied.
各文献がそれぞれ単独に引用されるように、本発明に係るすべての文献は本出願で参考
として引用する。また、本発明の上記の内容を読み終わった後、当業者が本発明を各種の
変動や修正をすることができるが、それらの等価の形態のものは本発明の請求の範囲に含
まれることが理解されるはずである。
All documents relating to the present invention are cited as references in this application, just as each document is cited independently. Further, after reading the above contents of the present invention, those skilled in the art may make various variations and modifications to the present invention, but those equivalent forms thereof are included in the claims of the present invention. Should be understood.
Claims (12)
的とする細胞外領域の抗体一本鎖可変領域の配列であることを特徴とする、前記キメラ抗
原受容体。 The chimeric antigen receptor, wherein the antigen-binding domain of the chimeric antigen receptor is a sequence of an antibody single-stranded variable region in an extracellular region targeting BCMA.
体一本鎖可変領域の配列であることを特徴とする、請求項1に記載のキメラ抗原受容体。 The chimeric antigen receptor according to claim 1, wherein the antigen-binding domain is a sequence of an antibody single-stranded variable region targeting amino acid residues 24 to 41 of the BCMA sequence.
のキメラ抗原受容体。
VL-VH (I)
(ただし、VHは抗体の重鎖可変領域で、VLは抗体の軽鎖可変領域で、「-」は連結
ペプチドまたはペプチド結合である。
かつ、VLのアミノ酸配列は配列番号1で示され、VHのアミノ酸配列は配列番号2で
示され、
あるいは、VLのアミノ酸配列は配列番号3で示され、VHのアミノ酸配列は配列番号
4で示され、
あるいは、VLのアミノ酸配列は配列番号5で示され、VHのアミノ酸配列は配列番号
6で示される。) The chimeric antigen receptor according to claim 1, wherein the structure of the antigen-binding domain is represented by the following formula I.
VL - VH (I)
(However, VE is the heavy chain variable region of the antibody, VL is the light chain variable region of the antibody, and "-" is a linked peptide or peptide bond.
Moreover, the amino acid sequence of VL is shown by SEQ ID NO: 1, and the amino acid sequence of VL is shown by SEQ ID NO: 2.
Alternatively, the amino acid sequence of VL is shown by SEQ ID NO: 3, and the amino acid sequence of VL is shown by SEQ ID NO: 4.
Alternatively, the amino acid sequence of VL is shown by SEQ ID NO: 5, and the amino acid sequence of VL is shown by SEQ ID NO: 6. )
載のキメラ抗原受容体。
S-VL-VH-H-TM-C-CD3ζ (II)
(ただし、
Sは任意のシグナルペプチド(すなわちsignal peptide)である。
Hはヒンジ領域である。
TMは膜貫通ドメインである。
Cは共刺激シグナル分子である。
CD3ζはCD3ζ由来の細胞内シグナル伝達配列である。
VHとVLはそれぞれ上記の通りである。) The chimeric antigen receptor according to claim 1, wherein the structure of the chimeric antigen receptor is represented by the following formula II.
S-V L -V H -H-TM-C-CD3ζ (II)
(However,
S is any signal peptide (ie, signal peptide).
H is a hinge region.
TM is a transmembrane domain.
C is a co-stimulation signal molecule.
CD3ζ is an intracellular signal transduction sequence derived from CD3ζ.
V H and V L are as described above, respectively. )
子が組み込まれているか、あるいは請求項1に記載のキメラ抗原受容体を発現することを
特徴とする宿主細胞。 A host comprising the vector according to claim 6, incorporating a foreign nucleic acid molecule according to claim 5 into a chromosome, or expressing the chimeric antigen receptor according to claim 1. cell.
ARを発現する、
請求項5に記載の核酸分子または請求項6に記載のベクターをT細胞内に形質導入する
ことによって、前記CAR-T細胞を得る工程、
を含むことを特徴とする、前記方法。 A method for producing CAR-T cells, wherein the CAR-T cells are the C according to claim 1.
Express AR,
A step of obtaining the CAR-T cells by transducing the nucleic acid molecule according to claim 5 or the vector according to claim 6 into T cells.
The above-mentioned method.
クター、または請求項7に記載の宿主細胞と、薬学的に許容される担体、希釈剤または賦
形剤とを含有することを特徴とする製剤。 The chimeric antigen receptor according to claim 1, the nucleic acid molecule according to claim 5, the vector according to claim 6, or the host cell according to claim 7, and a pharmaceutically acceptable carrier, diluent or the like. A preparation characterized by containing an excipient.
クター、または請求項7に記載の宿主細胞の使用であって、癌または腫瘍を予防および/
または治療する薬物または製剤の製造に使用されることを特徴とする、前記使用。 Use of the chimeric antigen receptor of claim 1, the nucleic acid molecule of claim 5, the vector of claim 6, or the host cell of claim 7 to prevent and / or prevent cancer or tumor.
Or said use, characterized in that it is used in the manufacture of a drug or formulation to be treated.
病であることを特徴とする、請求項10に記載の使用。 The use according to claim 10, wherein the tumor is BCMA-positive B-cell lymphoma, multiple myeloma, or plasmacytoid leukemia.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023098770A JP2023116716A (en) | 2018-04-12 | 2023-06-15 | Bcma-targeted chimeric antigen receptor, and preparation method and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810326346.9 | 2018-04-12 | ||
CN201810326346.9A CN110372796B (en) | 2018-04-12 | 2018-04-12 | Chimeric antigen receptor targeting BCMA and preparation method and application thereof |
JP2020531444A JP7148611B2 (en) | 2018-04-12 | 2019-04-02 | CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND METHOD FOR PRODUCING AND USE THEREOF |
PCT/CN2019/081064 WO2019196713A1 (en) | 2018-04-12 | 2019-04-02 | Bcma-targeted chimeric antigen receptor as well as preparation method therefor and application thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020531444A Division JP7148611B2 (en) | 2018-04-12 | 2019-04-02 | CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND METHOD FOR PRODUCING AND USE THEREOF |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023098770A Division JP2023116716A (en) | 2018-04-12 | 2023-06-15 | Bcma-targeted chimeric antigen receptor, and preparation method and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2022031784A true JP2022031784A (en) | 2022-02-22 |
JP2022031784A5 JP2022031784A5 (en) | 2022-09-15 |
JP7299294B2 JP7299294B2 (en) | 2023-06-27 |
Family
ID=68162957
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020531444A Active JP7148611B2 (en) | 2018-04-12 | 2019-04-02 | CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND METHOD FOR PRODUCING AND USE THEREOF |
JP2021190474A Active JP7299294B2 (en) | 2018-04-12 | 2021-11-24 | CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND METHOD FOR PRODUCING AND USE THEREOF |
JP2023098770A Pending JP2023116716A (en) | 2018-04-12 | 2023-06-15 | Bcma-targeted chimeric antigen receptor, and preparation method and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020531444A Active JP7148611B2 (en) | 2018-04-12 | 2019-04-02 | CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND METHOD FOR PRODUCING AND USE THEREOF |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023098770A Pending JP2023116716A (en) | 2018-04-12 | 2023-06-15 | Bcma-targeted chimeric antigen receptor, and preparation method and use thereof |
Country Status (9)
Country | Link |
---|---|
US (3) | US11142581B2 (en) |
EP (1) | EP3778651A4 (en) |
JP (3) | JP7148611B2 (en) |
KR (1) | KR20200142036A (en) |
CN (3) | CN110372796B (en) |
AU (2) | AU2019251016B2 (en) |
CA (1) | CA3095827A1 (en) |
SG (1) | SG11202009962UA (en) |
WO (1) | WO2019196713A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110372796B (en) * | 2018-04-12 | 2023-05-02 | 上海赛比曼生物科技有限公司 | Chimeric antigen receptor targeting BCMA and preparation method and application thereof |
CN111333732B (en) * | 2019-12-17 | 2023-02-28 | 中国药科大学 | Preparation and application of bispecific antibody targeting human BCMA and activating NK cells |
KR102371151B1 (en) * | 2020-03-13 | 2022-03-07 | 주식회사 큐로셀 | Anti-bcma-binding domains, fusion proteins comprising thereof, and compositions comprising thereof |
CN112851815B (en) * | 2020-03-17 | 2023-08-08 | 西安宇繁生物科技有限责任公司 | anti-BCMA antibody or antigen binding fragment thereof, and preparation method and application thereof |
CN113527507A (en) * | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | Chimeric antigen receptor targeting CD22 and preparation method and application thereof |
CN112251412B (en) * | 2020-10-12 | 2023-03-28 | 汤朝阳 | BCMA (brain cell activating antigen) targeted chimeric antigen receptor T cell and application thereof |
EP4255936A1 (en) * | 2020-12-02 | 2023-10-11 | Shanghai Cellular Biopharmaceutical Group Ltd. | Bcma-targeted chimeric antigen receptors |
US20220227832A1 (en) | 2020-12-21 | 2022-07-21 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
CN113173991B (en) * | 2020-12-31 | 2023-03-28 | 北京艺妙神州医药科技有限公司 | anti-BCMA antibody and application thereof |
MX2023008809A (en) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, ß2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS. |
WO2023167903A2 (en) * | 2022-03-01 | 2023-09-07 | Agilent Technologies, Inc. | Anti-human b cell maturation antigen (bcma) antibodies and their use in immunohistochemistry (ihc) |
US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
CN116444669B (en) * | 2023-04-04 | 2024-02-13 | 科弈(浙江)药业科技有限公司 | Humanized antibodies targeting BCMA CAR-T cells |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014520088A (en) * | 2011-05-27 | 2014-08-21 | グラクソ グループ リミテッド | BCMA (CD269 / TNFRSF17) binding protein |
WO2016166630A1 (en) * | 2015-04-13 | 2016-10-20 | Pfizer Inc. | Chimeric antigen receptors targeting b-cell maturation antigen |
JP2017522882A (en) * | 2014-07-24 | 2017-08-17 | ブルーバード バイオ, インコーポレイテッド | BCMA chimeric antigen receptor |
WO2017211900A1 (en) * | 2016-06-07 | 2017-12-14 | Max-Delbrück-Centrum für Molekulare Medizin | Chimeric antigen receptor and car-t cells that bind bcma |
JP2017538710A (en) * | 2014-12-12 | 2017-12-28 | ブルーバード バイオ, インコーポレイテッド | BCMA chimeric antigen receptor |
JP7148611B2 (en) * | 2018-04-12 | 2022-10-05 | セルラー・バイオメディシン・グループ・エイチケー・リミテッド | CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND METHOD FOR PRODUCING AND USE THEREOF |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
TWI679212B (en) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
US9765342B2 (en) * | 2012-04-11 | 2017-09-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting B-cell maturation antigen |
CA2945620C (en) | 2014-04-14 | 2022-12-06 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
CN105384825B (en) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
RU2018119706A (en) * | 2015-10-30 | 2019-12-02 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | FORECAST METHOD |
KR20230148844A (en) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | Chimeric Antigen Receptors Targeting Cancer |
EP3464375A2 (en) | 2016-06-02 | 2019-04-10 | Novartis AG | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
CN107827989A (en) * | 2017-10-18 | 2018-03-23 | 银丰生物工程集团有限公司 | Target transgenic T cells of myeloma BCMA antigens and preparation method and application |
-
2018
- 2018-04-12 CN CN201810326346.9A patent/CN110372796B/en active Active
- 2018-04-12 CN CN202310447932.XA patent/CN116514995A/en active Pending
- 2018-04-12 CN CN202310450645.4A patent/CN116836297A/en active Pending
-
2019
- 2019-04-02 JP JP2020531444A patent/JP7148611B2/en active Active
- 2019-04-02 CA CA3095827A patent/CA3095827A1/en active Pending
- 2019-04-02 SG SG11202009962UA patent/SG11202009962UA/en unknown
- 2019-04-02 EP EP19784803.9A patent/EP3778651A4/en active Pending
- 2019-04-02 WO PCT/CN2019/081064 patent/WO2019196713A1/en active Application Filing
- 2019-04-02 AU AU2019251016A patent/AU2019251016B2/en active Active
- 2019-04-02 KR KR1020207032269A patent/KR20200142036A/en unknown
-
2020
- 2020-05-22 US US16/881,668 patent/US11142581B2/en active Active
-
2021
- 2021-09-16 US US17/476,661 patent/US11498973B2/en active Active
- 2021-11-24 JP JP2021190474A patent/JP7299294B2/en active Active
-
2022
- 2022-09-23 US US17/951,774 patent/US20230053305A1/en active Pending
-
2023
- 2023-06-15 JP JP2023098770A patent/JP2023116716A/en active Pending
- 2023-06-29 AU AU2023204159A patent/AU2023204159A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014520088A (en) * | 2011-05-27 | 2014-08-21 | グラクソ グループ リミテッド | BCMA (CD269 / TNFRSF17) binding protein |
JP2017522882A (en) * | 2014-07-24 | 2017-08-17 | ブルーバード バイオ, インコーポレイテッド | BCMA chimeric antigen receptor |
JP2017538710A (en) * | 2014-12-12 | 2017-12-28 | ブルーバード バイオ, インコーポレイテッド | BCMA chimeric antigen receptor |
WO2016166630A1 (en) * | 2015-04-13 | 2016-10-20 | Pfizer Inc. | Chimeric antigen receptors targeting b-cell maturation antigen |
WO2017211900A1 (en) * | 2016-06-07 | 2017-12-14 | Max-Delbrück-Centrum für Molekulare Medizin | Chimeric antigen receptor and car-t cells that bind bcma |
JP7148611B2 (en) * | 2018-04-12 | 2022-10-05 | セルラー・バイオメディシン・グループ・エイチケー・リミテッド | CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND METHOD FOR PRODUCING AND USE THEREOF |
Also Published As
Publication number | Publication date |
---|---|
US20210403590A1 (en) | 2021-12-30 |
CN110372796B (en) | 2023-05-02 |
CN116836297A (en) | 2023-10-03 |
JP7299294B2 (en) | 2023-06-27 |
AU2019251016B2 (en) | 2023-08-10 |
JP7148611B2 (en) | 2022-10-05 |
AU2023204159A1 (en) | 2023-07-20 |
WO2019196713A1 (en) | 2019-10-17 |
KR20200142036A (en) | 2020-12-21 |
EP3778651A1 (en) | 2021-02-17 |
CN116514995A (en) | 2023-08-01 |
AU2019251016A1 (en) | 2020-10-22 |
SG11202009962UA (en) | 2020-11-27 |
US11498973B2 (en) | 2022-11-15 |
US20230053305A1 (en) | 2023-02-16 |
CN110372796A (en) | 2019-10-25 |
EP3778651A4 (en) | 2022-01-05 |
CA3095827A1 (en) | 2019-10-17 |
US20200362048A1 (en) | 2020-11-19 |
JP2021520185A (en) | 2021-08-19 |
JP2023116716A (en) | 2023-08-22 |
US11142581B2 (en) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7299294B2 (en) | CHIMERIC ANTIGEN RECEPTOR TARGETING BCMA AND METHOD FOR PRODUCING AND USE THEREOF | |
CN110950953B (en) | Monoclonal antibody against B7-H3 and application thereof in cell therapy | |
CN109575143B (en) | Bispecific CD20-CD19-CAR and application thereof | |
CN113087806B (en) | Novel CAR-T cells targeting multiple tumors, and preparation and methods thereof | |
CN113621582A (en) | Engineered immune cell for combined expression of CCR2b, and preparation and application thereof | |
CN113755448A (en) | Engineered immune cells jointly expressing CCR2b and CD40L, and preparation and application thereof | |
WO2023016524A1 (en) | Combined her2 and meso dual-target car-t vector, construction method therefor and application thereof in cancer | |
WO2023161846A1 (en) | Gpc3-targeting chimeric antigen receptor t cell and use thereof | |
US20230144447A1 (en) | Cd22-targeted chimeric antigen receptor, preparation method therefor and application thereof | |
CN114685683A (en) | GD 2-targeted CAR-T cells and preparation and application thereof | |
JP2022514815A (en) | CAR-T cells with humanized CD19 scFv mutated to the CDR1 region | |
CN116444669B (en) | Humanized antibodies targeting BCMA CAR-T cells | |
WO2022151959A1 (en) | Car-t cell targeting b7-h3 and application thereof in treatment of acute myeloid leukemia | |
CN116478929A (en) | Bispecific CAR-T cells targeting BCMA and CD19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220907 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20221021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20221021 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230309 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230523 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230615 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7299294 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |